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ABSTRACT OF THESIS 
 
 
ANALYSIS OF HUMORAL IMMUNE RESPONSES IN HORSES 
WITH EQUINE PROTOZOAL MYELOENCEPHALITIS. 
 
Equine protozoal myeloencephalitis (EPM), caused by the protozoan 
parasite Sarcocystis neurona, is one of the most important neurological diseases of horses 
in the Americas. While seroprevalence of S. neurona in horses is high, clinical 
manifestation of EPM occurs in less than 1% of infected horses. Factors governing the 
occurrence and severity of EPM are largely unknown, although horse immunity might 
play an important role in clinical outcome. We hypothesize that EPM occurs due to an 
aberrant immune response, which will be discernable in the equine IgG subisotypes a, b, 
and (T) that recognize S. neurona in infected diseased horses versus infected but 
clinically healthy horses.  Based on previously-established serum antibody concentrations 
for IgG subisotypes in healthy horses, standard curves were generated and served to 
establish the concentration of antigen-specific IgG subisotypes in equine serum and CSF 
in infected diseased and infected normal horses. The subisotype concentrations and ratios 
between subisotypes were analyzed to assess whether neurological disease is associated 
with detectable differences in the antibody response elicited by infection. Results indicate 
a type I biased immune response in infected diseased horses, implicating the role of 
immunity in the development of EPM. 
KEYWORDS: Equine Protozoal Myeloencephalitis; Sarcocystis neurona; 
immunopathology; immunoglobulin; horse 
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Chapter 1: The Parasite  
1.1 Protozoal Parasites 
Protozoa are single celled eukaryotic organisms. Despite their small size, protozoa are 
responsible for causing major disease worldwide. Malaria, caused by Plasmodium spp., is 
a severe disease causing fever, and sometimes death, with 3.2 billion people living in at-
risk areas globally. Toxoplasmosis, caused by Toxoplasma gondii, is a human pathogen 
well-known to cause disease in immunocompromised patients and those suffering from 
acquired immune deficiency syndrome (AIDS), and can be transmitted transplacentally in 
pregnant women. African sleeping sickness, caused by Trypanosoma brucei, is a disease 
prevalent in sub-Saharan African, resulting in neurological disease and death, if 
untreated. Cryptosporidiosis, caused by Cryptosporidium spp., is the leading cause of 
waterborne disease in the United States. Protozoan diseases have also been well 
characterized in the horse: Equine piroplasmosis is a tick-borne disease caused by 
Babesia equi/Theileria caballi, affecting all equids. Dourine is a sexually transmitted 
disease caused by Trypanosoma equiperdum, with high mortality in acutely infected 
breeding animals. Surra, caused by Trypanosoma evansi, is of great global importance 
due to economic losses from decreased productivity in working animals and reproductive 
losses. Equine Protozoal Myeloencephalitis (EPM), caused by Sarcocystis neurona, is an 
important neurological disease of horses in the Americas. It is EPM, its etiologic agent, 
and its host that will be the focus of this paper. 
1.2 Phylum Apicomplexa 
EPM is largely caused by the protozoa Sarcocystis neurona, which is a member of the 
phylum Apicomplexa. Apicomplexa includes over 5,000 protozoa, of which almost all 
are obligate intracellular pathogens, infecting vertebrate and invertebrate species (Blader 
et al., 2015). Also in this phylum are the aforementioned genera Plasmodium, Babesia, 
Toxoplasma, and Cryptosporidium. Sarcocystis species are closely related to both 
Toxoplasma gondii and Neospora species. Due to its ease of use, the availability of 
genetic tools and excellent animal models, and because of its importance as a human 
pathogen, T. gondii has been the focus of much research within the phylum Apicomplexa 
(Dubey et al., 2015). It is somewhat fortunate for those working on Sarcocystis species 
that much of the research applied to Sarcocystis can be drawn from that conducted in 
Toxoplasma. This transfer of research tools across genera is applicable due to the genetic 
similarities between Toxoplasma and Sarcocystis. However, it must be noted that there 
are known inherent differences between these two parasites, and not all biological 
mechanisms and host responses can be assumed to be identical. 
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Figure 1.2.1 Phylogenetic tree of the phylum Apicomplexa, showing relative relatedness 
of Apicomplexan genera found in the blood, gut, and tissue of host animals.  
1.3 Sarcocystis species 
Sarcocystis is arguably the most successful protozoan parasite genus in nature, with the 
potential to infect all vertebrates, including fish, reptiles, birds, and mammals (Dubey et 
al., 2015). In general, they convey low pathogenicity, and infections are well tolerated 
(Dubey et al., 2016), although this is not always the case. Within the phylum 
Apicomplexa, Sarcocystis spp. are obligate intracellular parasites that are capable of 
causing disease in humans and animals, and can be found in muscles and the central 
nervous system (CNS) (Dubey et al., 2016). The life cycle is obligatorily two host, with 
asexual reproduction occurring in the intermediate host, and sexual reproduction and the 
expulsion of sporocysts occurring in the definitive host (Dubey et al., 2016). 
Sarcocystis spp. are well known in the livestock industry, with Sarcocystis cruzi, 
Sarcocystis tenella, and Sarcocystis capracanis causing decreased weight gain, and 
occasionally abortion and death, in cattle, sheep, and goats, respectively (Dubey et al., 
2016), and Sarcocystis aucheniae forming cysts in the muscle of camelids, resulting in 
the condemnation of carcass meat and economic loss for producers (Dubey et al., 2016). 
1.4 Economic Losses due to Sarcocystis Infections 
Globally, the main economic costs due to Sarcocystis infection come from the 
condemnation and downgrading of meat containing visible sarcocysts otherwise 
designated for consumption. This cost is estimated to be in the millions of dollars. 
However, the true economic losses are challenging to calculate as no monetary values can 
be placed on poor feed efficiency, reduced milk or wool production, and reproductive 
problems. Clinical disease due to Sarcocystis can be difficult to diagnose, and therefore 
the true cost of treatment is also ambiguous (Dubey et al., 2016). Estimates of the annual 
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cost due to S. neurona infection in the horses were calculated in 1998 by the Animal and 
Plant Health Inspection Service, and are addressed in the following chapter.  
1.5 Life Cycle of Sarcocystis neurona 
Like most members of the Phylum Apicomplexan, all Sarcocystis species have an 
obligate intracellular heteroxenous life cycle involving both sexual and asexual stages of 
reproduction, with each stage of reproduction occurring in one or more different host 
animal. The sexual stage of reproduction occurs in the gastrointestinal tract of the meat 
eating definitive host, which for S. neurona is the metatherian North and South American 
opossums (Didelphis virginiana and Didelphis albiventris, respectively) (Dubey et al., 
2015). Whether other species of South American opossum are definitive hosts is not yet 
known (Dubey et al., 2015). Between 6%-31% of opossums tested in the United States 
were found to harbor sporocysts (described later in this section) (Dubey et al., 2016).  
In the definitive host, the bradyzoite stage of the parasite actively moves to penetrate the 
lining of the small intestine. Here parasites differentiate into micro (male) and macro 
(female) gamonts in preparation for sexual reproduction. Through the process of 
fertilization, microgametes move to the periphery of the macrogamont, where their 
membranes fuse and the nucleus of the microgamont is transferred into the macrogamont 
to create a zygote. A wall develops around the zygote, and an oocyst, or sporocyst, is 
formed (Dubey et al., 2016). Sporocysts are released into the lumen of the intestine and 
are then shed into the environment through opossum feces, where they can be picked up 
by the intermediate hosts.  
The asexual stage of reproduction occurs in the intermediate host, of which there are 
many for S. neurona. The opossum is the only known definitive host for S. neurona, but 
unlike other Sarcocystis spp. S. neurona has numerous intermediate hosts, including 
skunks (Mephitis mephitis), raccoons (Procyon lotor), armadillos (Dasypus 
novemcinctus), and cats (Felis catus) (Dubey et al., 2015). Intermediate hosts become 
infected with S. neurona sporocysts by ingesting food or water contaminated by infected 
opossum feces (Dubey et al., 2016; Fenger et al., 1995). In the intermediate host, 
sporozoites enter intestinal epithelial cells, where they undergo the first stages of asexual 
reproduction (Fenger et al., 1995). Upon entering the host epithelial cells, the sporozoites 
transform into oval schizonts. Unlike other intracellular stages of Sarcocystis spp., 
schizonts are located free within the cytoplasm of the host cell, and are not surrounded by 
a parasitophorous vacuole (distinguishing it from T. gondii) (Dubey et al., 2016). 
Schizonts undergo endopolygamy, and release 64 merozoites into the cell. The host cell 
is unable to sustain 64 merozoites, and dies, releasing the parasites into the blood stream. 
Merozoites spread throughout the body, and are usually controlled by a potent immune 
response (Blader et al., 2015). It is possible that it is this immune response, in 
combination with the microenvironment of myocytes that trigger the differentiation of S. 
neurona merozoites into bradyzoites.  
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Sarcocyst development starts when merozoites enter a muscle or neural cell (Dubey et al., 
2016). The intracellular merozoite is surrounded by a parasitophorous vacuole, which 
becomes the external wall of the sarcocyst. After multiple divisions, the sarcocyst is filled 
with the bradyzoite, or slow-growing, form of the parasite, which ultimately become the 
infective stage for the definitive host (Dubey et al., 2016). Because they contain the 
infectious bradyzoites, sarcocysts are essential for the completion of the parasite’s life 
cycle, and have been found in intermediate host skeletal muscles, cardiac muscles, and 
brain (Dubey et al., 2015). Sarcocysts usually persist in the body of the intermediate host 
for the life of the host, although rupture of sarcocysts can occur, resulting in the release of 
bradyzoites, but does not initiate new development of sarcocysts (Dubey et al., 2016). 
Bradyzoites are non-infective to the intermediate host, or between intermediate hosts 
(Dubey et al., 2016). When the intermediate hosts die, they are scavenged by the 
definitive host. The definitive host becomes infected when it ingests muscular or neural 
tissue from an intermediate host containing mature sarcocysts. The sarcocysts are 
encysted in the intestines of the opossum, where they restart their life cycle.  
The only known means by which a definitive host can acquire a S. neurona infection is 
through the ingestion of mature sarcocysts containing the infectious bradyzoite form of 
the parasite. Immature sarcocysts and schizonts are not infectious for the definitive host 
(Dubey et al., 2016). Sarcocystis spp. do not generally cause illness in their definitive 
hosts (Dubey et al., 2016). Opossums are opportunistic scavengers, and rely heavily on 
dead animals for their diet, making the natural S. neurona life cycle highly efficient (Furr 
and Reed, 2015). 
It is only the sporozoite-containing sporocyst shed through opossum feces that is 
infectious to the intermediate host. Intermediate hosts do not shed parasites into the 
environment, and can therefore not pass the parasite from one animal to another. 
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Figure 1.5.1 (left) 
Fluorescence images of 
S. neurona. Transgenic 
clone of Sarcocystis 
neurona expressing 
yellow fluorescent 
protein. Differential 
interference contrast 
image with 
epifluorescence image 
overlay showing a bovine 
turbinate cell monolayer 
containing a late-stage 
schizonts and a mature 
schizont of a clone of S. 
neurona that stably 
expressed YFP. Host cell 
and parasite nuclei were 
stained with DAPI 
(blue). Bar-10µm. 
(Dubey et al., 2015).
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horse. There is seemingly no benefit to the parasite to infect the horse, and horses are 
therefore considered to be aberrant, accidental, or dead-end natural hosts of Sarcocystis 
neurona (Fenger et al., 1995). 
Although transplacental infection of Sarcocystis spp. has been documented in some host 
animals (most notably cattle and sheep), it is uncommon, and has not been reported in the 
horse (Dubey et al., 2016). 
1.7 Distribution 
The distribution of Sarcocystis neurona is dependent on its definitive host, Didelphis 
virginiana and Didelphis albiventris in North and South America, respectively. This 
makes it largely a disease of the Americas, although there have been reports of horses 
that have been exposed to the parasite while in the Americas and go on to develop 
clinical disease when in another country (Dubey et al., 2015). Within the United States, 
there is a high prevalence of antibodies to S. neurona, with seroprevalence being lower 
outside of the habitat range of the opossum (such as the intermountain west) and reaching 
almost 90% in some areas of high opossum densities (such as Oklahoma) (Dubey et al., 
2015). In Central and South America, studies have shown that horses often have 
regionally high exposure rates (Dangoudoubiyam et al., 2011; Hoane et al., 2006). 
 
Copyright © Catherine-Jane Angwin 2017 
 
   
8 
 
Chapter 2: Equine Protozoal Myeloencephalitis  
2.1 Disease Description 
Equine Protozoal Myeloencephalitis (EPM) is most commonly caused by the etiologic 
agent Sarcocystis neurona, and is one of the most important neurological diseases of 
horses in the Americas. EPM was originally referred to as “segmental myelitis,” and was 
first described by Rooney et al. in 1970 (Rooney et al., 1970). It was discovered to be of 
protozoan etiology in 1974, although it was not known to be caused by S. neurona until 
1991 (Dubey et al., 2016). Although there are many neurologic disorders that affect the 
horse, EPM is one of the most commonly diagnosed (Dubey et al., 2015). 
While the seroprevalence of S. neurona in horses is high, clinical manifestation of EPM 
occurs in less than 1% of the infected horses (MacKay et al., 2000; NAHMS, 2001). It is 
therefore apparent that neurological disease is not the outcome of every S. neurona 
infection. 
It is likely that clinical disease due to S. neurona is rare because pathology is caused by 
the merozoite stage of the parasite attempting to invade cells, and this stage is typically 
well-controlled by the host immune response (Blader et al., 2015). 
EPM is rare in non-horse equids, but, as mentioned later in this chapter, can affect 
animals other than the horse, and is a common cause of mortality in marine mammals 
(Dubey et al., 2015). 
2.2 Clinical Signs 
Although EPM is usually a progressively debilitating disease with a gradual onset, this 
varies widely from horse to horse. The disease may stabilize in some horses, remaining 
static for periods of time, but in others it can have a rapid onset with focal or multifocal 
signs of neurologic disease (Dubey et al., 2015). Early clinical signs of disease can 
include stumbling and are often confused with hind end lameness (Dubey et al., 2015). 
Gradual progression of clinical signs includes ataxia, asymmetric weakness, abnormal 
upper airway function, and hypoalgesia. Neurological symptoms can include head tilting, 
facial nerve paralysis, seizures, and, in more severe cases, difficulty swallowing. The 
location and severity of clinical signs depends on the localization of the damage in the 
central nervous system (CNS), and damage can occur in the brain, brainstem, spinal cord, 
or any combination of the areas of CNS (Dubey et al., 2015). For example, behavioral 
changes or seizures are caused by damage to the cerebrum, lesions in the brainstem and 
spinal cord can cause gait abnormalities and incoordination; and damage to gray matter in 
the brain, which controls the nerves running to limb muscles, produces weakness and 
atrophy of innervated muscles. This is particularly true of the hind end gluteal or 
temporalis muscles, which are often atrophied asymmetrically (Dubey et al., 2015). 
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2.3 Lesions 
Upon necropsy, in some EPM cases parasites can be numerous and easily found in the 
CNS. However, in other cases, even those with severe lesions, parasites are sparse or 
non-detectable. This implies that pathogenesis is, at least in part, immune-based (Dubey 
et al., 2015; Furr and Reed, 2015)  
It is therefore likely that it is not the parasite itself that causes damage within the CNS, 
but rather the host immune response to the parasite. When a cell is invaded, a trigger is 
given to the immune response to kill the infected cell. When this occurs, it is not this 
singular cell that is destroyed, but also surrounding cells are subject to collateral damage. 
Thereby, this immune response often results in lesions, and therefore CNS damage. 
Lesions due to S. neurona infection do not always occur, but when they do, they are 
confined to the CNS (Dubey et al., 2015). The brainstem is the most commonly affected 
region of the brain, yet lesions are more frequently seen in the spinal cord (Dubey et al., 
2015). These lesions often result in the previously described gait abnormalities typically 
seen in clinical EPM cases. 
Both gross and/or microscopic lesions can occur. Gross lesions typically consist of areas 
of hemorrhage, sometimes with mild swelling. Microscopic lesions predominantly 
contain lymphocytes and macrophages, but eosinophils are commonly present, and are 
often accompanied by inflammation and tissue degeneration (Dubey et al., 2015). 
 
Figure 2.3.1 Cut view of cerebrum of a 20-year-old Paint horse with histologically 
and PCR confirmed EPM. The horse had a six-day history of muscle fasciculations, 
bruxism, difficulty eating and drinking, and circling to the left with head pressing. 
Note hemorrhagic and yellow discolored areas indicative of necrosis. Bar = 5mm 
(Dubey et al., 2015). 
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2.4 Infectivity and Central Nervous System Access 
Parasites with a two-host life cycle are thought to manipulate physiological responses in 
the intermediate host, in order to more effectively and efficiently reach the definitive 
host, where they can complete their life cycle through sexual reproduction (Berdoy et al., 
2000). In order to enter and exit the cell at will, and obtain nutrients, intracellular 
pathogens require interactions with the host cell, yet simultaneously avoid setting off 
signals that would result in their elimination, and must therefore manipulate innate 
immune mechanisms (Sibley, 2011). 
In horses with EPM, Sarcocystis neurona parasites are able to parasitize all regions of the 
CNS, and may be found in neurons, mononuclear cells, and glial cells (Sellon et al., 
2004). Because the horse acquires the parasites through contaminated food or water 
sources, the parasites must therefore reach the CNS from the gastrointestinal tract. As 
previously mentioned, S. neurona invades intestinal epithelial cells and disseminates into 
the blood. However, parasitemia in horses is rarely noted in naturally infected horses 
(Dubey, 2001; Sellon et al., 2004), and in studies conducted in mice, parasites were found 
to be in the CNS after 13 days of infection (Dubey, 2001). Therefore, to reach the CNS 
cells, the parasite must not only evade the immune system, but also gain access to the 
highly protected CNS. As mentioned later in this document, the blood-brain barrier is a 
barrier largely composed of tightly-associated brain endothelial cells. There are three 
ways to cross the blood-brain barrier: through the endothelial cells (transcellularly), 
between the endothelial cells (paracellularly), or inside another cell that is actively 
transported across the endothelial cells (Kim, 2008). The etiologic agents of African 
sleeping sickness, Protozoan parasites Trypanosoma brucei gambiense and Trypanosoma 
brucei rhodesiense, gain access to the CNS paracellularly or transcellularly (Kim, 2008). 
With Apicomplexan parasites, the relationship with endothelial cells can vary widely – 
from direct invasion and lysis (as seen in T. gondii), initial replication within these cells 
(as seen with some avian and reptilian Plasmodium spp.), to the adhesion of infected 
erythrocytes allowing for parasite sequestration (as seen with P. falciparum and Babesia 
spp.) (Konradt et al., 2016). Each of these interactions reflects different strategies that 
have arisen through evolution of the parasite-host relationship for immune evasion and to 
facilitate transmission into an immune privileged site (Konradt et al., 2016). 
Research in into T. gondii has demonstrated two broad mechanisms of gaining entry: the 
“Trojan horse” theory, and the direct invasion theory. It is likely that these are not 
mutually exclusive and that parasites in fact employ a combination of both methods. Due 
to the similarity of S. neurona to T. gondii, it is not unreasonable to assume that S. 
neurona employs similar mechanisms of entry. 
“Trojan horse” theory 
T. gondii is thought to exploit host monocytic or dendritic cells to allow for transportation 
across the BBB, in a “Trojan Horse” fashion (Lachenmaier et al., 2011). T. gondii 
infection results in upregulation of the transcriptome, which, increases the cytokines, 
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2.6 Risk Factors for Disease / Epidemiology 
Seroprevalence to S. neurona across the United States is high, and increases with age 
(Saville et al., 1997). Yet less than 1% of these animals go on to develop clinical EPM 
(NAHMS, 2001). As yet, it is not clear what the risk factors are that lead to the 
occurrence and severity of EPM in this small percentage of horses and not others. 
Additionally, because these risk factors are largely unknown, it has been difficult to 
reliably induce disease experimentally in horses (Dubey et al., 2015). 
EPM typically occurs in individual cases, and not in outbreaks, although there is a 
regional ecology associated with the disease, with more cases occurring where there are 
higher populations of opossums (Furr and Reed, 2015; Morley et al., 2008). Sporocysts 
shed into the environment are resistant to freezing (Dubey et al., 1978) and to 
disinfectants (McKenna and Charleston, 1992), meaning they can survive on a pasture 
over winter or in a feed storage area for months, even when opossums may not be seen to 
be active (Savini et al., 1996). 
The average age of horses affected with EPM is approximately 3.5 to 4.5 years old, 
although all horses are believed to be susceptible to disease development (Boy et al., 
1990; Dubey et al., 2015). However, there are no confirmed reports of clinical EPM in 
horses under 6 months of age (Dubey et al., 2015). There are also no documented cases 
of congenital transmission of S. neurona infection in land mammals (Dubey et al., 2015). 
Stress, notably in the form of pregnancy, lactation and weather, is known to have effect 
on the susceptibility to infection and severity of disease in animals infected by other 
Sarcocystis species (Dubey et al., 2016). Research into the effects of transportation stress 
on horses has led the conclusion that stress can induce clinical disease in the horse. 
Horses transported by road for 55 hours were dosed with S. neurona sporocysts as the 
horses were unloaded at their destination. The transported horses seroconverted to 
become S. neurona positive sooner than non-transported horses, and exhibited more 
severe clinical signs (Saville et al., 2001). This is likely because stress leads to immune 
suppression, which is commonly implicated in protozoan parasite infections (Furr and 
Reed, 2015). However, a second study placing horses under a second round of 
transportation-induced stress did not see any difference in the severity of clinical signs 
(Saville et al., 2004). 
Non-transport-induced stress was tested in horses experimentally treated with 
immunosuppressant drugs. There was no difference in the CNS histopathology between 
immunosuppressed and non-immunosuppressed horses, although the treated horses were 
found to have more severe clinical signs (Cutler et al., 2001). 
While the role of stress on clinical outcome of S. neurona infection cannot be ruled out, it 
is clear this is a complex relationship, further complicated by limited understanding of the 
equine immune system. 
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The outcome of most Sarcocystis infections is dependent on the dose, and is species 
dependent (Dubey et al., 2016). However, studies in the horse found that clinical outcome 
was not dose dependent, with disease arising from infection by as few as 100 sporocysts 
(Sofaly et al., 2002). 
Neither nutritional status nor concurrent infection seems to be associated with clinical 
EPM (Dubey et al., 2015). It is reasonable to assume that any modulation of immune 
responses by other pathogens may play a role in how the host responds to S. neurona 
infection, but this warrants further research and is beyond the scope of this document. 
Therefore, risk factors assumed to be governing the development of clinical EPM 
include: age, stress, and exposure to opossums and their feces (Morley et al., 2008). 
However, the only risk factor for EPM that can be claimed with any certainty is the last - 
living, or having lived in, the geographic range of the definitive host, making EPM a 
disease of the Americas. Therefore, horses in other countries should have no exposure to 
S. neurona (Dubey et al., 2015), and most horses that test positive for the parasite outside 
of the endemic Americas have spent time within those regions (Furr and Reed, 2015).  
Testing for S. neurona has come back positive in a group of horses from France and 
Spain (Arias et al., 2012; Pitel et al., 2002), and this is likely due to cross-reactivity with 
another Sarcocystis species found to be endemic to Europe (Dubey et al., 2015). 
Horse immunity is considered to play an important role in clinical outcome, although at 
present, little research has been conducted into the host immune response to S. neurona 
(Dubey et al., 2015). This will be further addressed later in this document. 
2.7 Diagnosis of EPM 
Antemortem diagnosis of EPM has proven challenging for numerous reasons. Actual 
pathogenesis of the disease is not clear, and S. neurona parasites have not been found in 
affected muscles (Dubey et al., 2015). Parasitemia is rare in infected horses, making it 
almost impossible to detect parasites microscopically in serum, in contrast to diseases as 
malaria, where blood stages of Plasmodium spp. are clearly visible.  
Because seroprevalence to S. neurona is variably high across the Americas, detecting 
parasite-specific serum antibodies is of little diagnostic use, as it is clear that infection 
does not equal disease (Dubey et al., 2015; Furr et al., 2002). Although analysis of 
parasite-specific cerebrospinal fluid antibodies may have more diagnostic use, as high 
levels of CNS antibodies are often indicative of CNS infection and intrathecal antibody 
production, it is not usually diagnostically conclusive. In the healthy horse, antibodies 
transfer passively across the blood-brain barrier at low levels. If the blood-brain barrier 
has been compromised by some other type of infection, it is also possible that antibodies 
will transfer across in higher numbers. Blood contamination during CSF collection may 
also confuse diagnostic potential (Furr et al., 2002). 
The early clinical signs of EPM can easily be confused with lameness issues, which add 
to the ambiguity, particularly as lameness issues are far more prevalent than neurological 
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disorders. To diagnose EPM with confidence, a full clinical veterinary evaluation must be 
conducted, including radiographs, serology, CSF collection, a lameness exam, serum 
chemistry profiling, and historical information. If EPM is suspected, a veterinarian must 
be consulted for the following three steps. 1) Conducting a full neurologic exam. The 
veterinarian will look for the three A’s of atrophy, asymmetry, and ataxia (Furr and Reed, 
2015). These are signs that are classical of neurologic disease, rather than a disease of the 
musculoskeletal system. 2) If there is cause to believe neurological damage has occurred, 
other potential causes for disease should be eliminated to help direct a full diagnostic 
evaluation. Other diseases to be ruled out include viral or bacterial neurological disease, 
particularly if an outbreak is known to have occurred in the area (Furr and Reed, 2015). 
Both serum and CSF should be evaluated. If all such testing is negative, the probability of 
EPM increases, which leads to step three. 3) immunodiagnostic testing to demonstrate the 
presence of antibodies against S. neurona in serum and CSF to assess intrathecal 
production (Furr and Reed, 2015). Neither serum nor CSF alone are good indicators of 
EPM, because horses can have a high antibody titer in serum, and therefore also in CSF 
due to passive transfer of lymphocytes (addressed in Chapter 3). Therefore, it is 
important to have both samples for accurate diagnostic testing. To obtain a CSF sample, a 
spinal tap must be performed by an experienced veterinarian. Although the steps are 
listed chronologically, they are usually carried out during the same veterinary consult. 
2.8 Diagnostic Assays 
More accurate diagnosis of EPM became possible with the development of the 
serological assay, the Western blot (immunoblot) assay. Since its development, several 
serological assays have been developed and are commercially available in laboratories 
across the Americas. The development of semi-quantitative assays allows for the 
detection of intrathecal antibody production against S. neurona, which can be compared 
to serum derived antibody production, for the accurate identification of EPM horses (Furr 
and Reed, 2015). 
Western Blot (Immunoblot) 
This assay was first developed for use in EPM diagnosis in 1993, and has therefore now 
been available for over two decades. Although it continues to be offered by several 
diagnostic testing laboratories, primarily a research tool that is fairly laborious and 
requires significant expertise to interpret accurately. It has lower sensitivity and 
specificity than subsequently developed diagnostic assays (Dubey et al., 2015).  
Enzyme-Linked Immunosorbent Assays (ELISAs) 
Sarcocystis neurona merozoites express a family of surface antigens (SnSAGs) that are 
abundant and immunogenic. SnSAGs can be produced in recombinant form for use in 
diagnostic tools, such as the ELISA. 
SnSAGs elicit a strong humoral immune response in infected animals, and are therefore 
used as a target molecule in immunological serum assays for the detection of antibodies 
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against S. neurona (Dubey et al., 2016). Not all strains of S. neurona express the same 
surface antigen, with SnSAGs 1, 5, and 6 being mutually exclusive in strains occurring in 
nature. SnSAGs 2, 3, and 4, however, are located on the surface of the extracellular 
merozoite stage, and are present throughout the intracellular development of the schizont 
as well (Dubey et al., 2016). 
Different strains of the S. neurona parasite display antigenic diversity, meaning that not 
all SnSAGs occur in all strains of S. neurona (Dubey et al., 2016). Using just one 
SnSAG, or a combination that will not cover the range of diversity, will be of little 
diagnostic value. SnSAG2, SnSAG3, and SnSAG4 are highly conserved proteins that 
exhibit little or no sequence polymorphism across parasite strains. SnSAG3 and SnSAG4 
have been fused into one chimeric protein, facilitating diagnostic assays. This chimeric 
protein is used as part of a two-ELISA commercially available test (with the other ELISA 
testing for SnSAG2) for EPM (Dubey et al., 2015). More recently, the trivalent protein 
rSnSAG2/4/3 has been developed, showing ample specificity and sensitivity in detecting 
S. neurona antibodies (Yeargan et al., 2015). The diagnostic accuracy of this assay is 
93% sensitivity and 83% specificity (Reed et al., 2013). By using either of these assays to 
test serum and CSF samples, and comparing the two, thus determining intrathecal 
antibody production (discussed later), EPM can be efficiently and effectively diagnosed.   
Immunohistochemistry (IHC) 
In tissues collected post-mortem, S. neurona schizonts and merozoites, the two parasite 
stages found in the horse, are stained with either polyclonal or monoclonal antibodies 
specifically against culture-derived S. neurona merozoites. Not all S. neurona organisms 
in EPM cases will stain by immunohistochemistry,  and it must be remembered that 
parasites are often sparse or undetectable in the tissues of EPM horses (Dubey et al., 
2015). 
Immunofluorescent Antibody Test (IFAT) 
The Indirect Fluorescent Antibody Test (IFAT) for EPM was optimized and validated at 
the University of California, Davis. This test requires a fluorescence microscope, which 
is specialized equipment requiring expertise in interpretation of parasite fluorescence. 
When conducted by individuals with proper training and expertise, results from this type 
of test are accurate. It is available for commercial use at the University of California 
Veterinary Diagnostic Laboratory (Dubey et al., 2015) and the University of Kentucky 
Diagnostic Laboratory. As with any other serological assay for EPM, confirmation of a 
serum antibody titer alone is of little diagnostic value. However, when used to test both 
serum and CSF antibody titers and compare the ratio to determine intrathecal antigen-
specific antibody production, the IFAT can be a useful diagnostic tool. 
The Goldman-Witmer coefficient (C-value) 
The C-value and the antigen-specific antibody index (AI) are algorithms used to 
determine whether there is a greater concentration of pathogen-specific antibody in the 
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CSF than would normally be present through passive transfer of the blood-brain barrier 
of a healthy animal. These studies have been corroborated with the SnSAG ELISAs, and 
have mostly been abandoned in favor of the latter, which are inexpensive and less 
cumbersome to perform (Dubey et al., 2015). 
2.9 Treatment of EPM 
Because much of the damage to the equine CNS is due to the inflammatory response, 
treatment of horses suspected to have EPM must be done as quickly as possible. If 
administered promptly upon diagnosis, treatment results in successful recovery of 70-
75% of horses (Dubey et al., 2001). The most common treatments are antiprotozoal 
drugs, of which there are three approved by the Food and Drug Administration on the 
market: ponazuril, diclazuril, and a sulfadiazine/pyrimethamine combination, under 
respective brand names. Bioavailability of the anti-protozoals ponazuril and diclazuril has 
been tested, and they have been found to cross the blood-brain barrier. 
Ponazuril 
The oral paste ponazuril (Marquis®, Bayer) was the first FDA-approved medication for 
EPM. Ponazuril is thought to act as a coccidiostat by inhibiting apicoplast and/or 
mitochondrial function in the S. neurona parasite (Mitchell et al., 2005). Toxicity studies 
have found ponazuril to be very safe, with no systemic toxicity, even at doses six times 
higher than recommended (Kennedy et al., 2001). 
Diclazuril 
Diclazuril (Protazil®, Merck Animal Health) is chemically similar to ponazuril, but 
instead of an oral paste, is administered through alfalfa-based pellets that are top dressed 
in the daily grain ration (Dubey et al., 2015). Diclazuril has also been shown to be an 
EPM preventative in a study conducted on foals fed medicated pellets daily from 1-12 
months. Naturally exposed foals fed diclazuril had significantly reduced seroconversion 
to S. neurona than foals without medicated pellets (Pusterla et al., 2015). 
Sulfadiazine/Pyrimethamine 
The combination of sulfonamide and pyrimethamine (S/P) has been widely used over the 
past four decades, and has been known to treat to cerebral toxoplasmosis in humans. In 
humans, the drug can cross the blood-brain barrier, making it bioavailable. Although this 
has not been tested in the horse, it is proposed to have the same capabilities. A pre-mixed 
S/P combination is commercially available as the oral suspension ReBalance® (PRN 
Pharmacal). The cooperative anti-folate effects of sulfadiazine and pyrimethamine block 
nucleic acid and amino acid synthesis, ultimately leading to parasite death (Dubey et al., 
2015). Although less expensive than the coccidiostats, this compound requires 
administration for a prolonged period, and has been known to have toxic side effects, 
including anemia, leukopenia, fetal loss, and fetal abnormalities (Dubey et al., 2015).  
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Immunostimulants 
Immunostimulants and immunomodulators have been proposed as a disease treatment on 
the presumption that immunosuppression is a component of EPM pathophysiology. 
However, to date, there has been no conclusive evidence as to their success, and there are 
no such treatments FDA approved or commercially available for use in EPM horses. 
There is currently no commercially available vaccine for EPM, and undoubtedly the best 
treatment for EPM is prevention. As previously mentioned, up to 31% of opossums 
harbor S. neurona sporocysts, and a single opossum can shed millions of sporocysts in 
their feces for months (Dubey et al., 2016). Sporocysts are resistant to most 
environmental influences, and special measures must be taken to kill them, such as 
heating at 60C for one minute, heating at 55°C for 15 mins, or using 100% ammonium 
hydroxide (Dubey et al., 2016; Dubey et al., 2015). Therefore, reducing opossum access 
to feed and water sources is the best method of prevention. 
2.10 Relapse 
Horses can relapse with clinical EPM, with clinical signs similar to previous episode/s, 
even after prolonged therapy. It is currently not clear why relapse occurs. In Toxoplasma 
gondii infections, the bradyzoite containing cysts harbor latent infection without 
generating disease. Immunosuppression can result in these bradyzoites converting back to 
the tachyzoite stage of the parasite, which is responsible for the tissue destruction 
resulting in clinical disease (Blader et al., 2015). However, sarcocysts do not form in 
equine tissue. It is unknown whether schizonts can remain dormant in equine tissues 
(Dubey et al., 2015). 
2.11 Sarcocystis neurona and Marine Mammals 
Although not the focus of this particular study, it should be mentioned that S. neurona is 
also known to infect marine mammals. As well as caused by Toxoplasma gondii, 
protozoal encephalitis due to S. neurona is an important cause or mortality in sea otters 
on the western coast of the United States, which is consistent with the distribution of 
opossums (Dubey et al., 2015). Most notably, a large epizootic occurred during a 3-week 
period in 2004, resulting in the death of approximately 2% of the federally listed 
threatened southern sea otter (Enhydra lutris neresis) population (Miller et al., 2010). S. 
neurona caused encephalitis has also been reported in pacific harbor seals (Phoca vitulina 
richardsi) and pacific harbor porpoises (Phocoena phocoena). As in the case of the horse, 
infection with the S. neurona parasite does not necessarily mean clinical disease. 
Infection, although not necessarily clinical signs, have been found in a wide variety of 
other marine mammals, including the California sea lion (Zalophus califonianus), 
Guadalupe fur seals (Arcocepahlus townsendi), Steller sea lions (Eumatopias jubatus), 
Northern fur seals (Callorhinus ursinus), Northern elephant seals (Mirounga 
angustirostris), a Pacific white sided dolphin (Langenorthynchus obliquidens), a killer 
whale (Orcinus orca), and a pygmy sperm whale (Kogia breviceps) (Barbosa et al., 
2015). 
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2.12 Neospora caninum and Neospora hughesi 
Neospora caninum and Neospora hughesi infections may also cause neurologic disease 
that is clinically indistinguishable from that caused by S. neurona. However, infections 
by S. neurona appear to be a much more frequent cause of EPM (Morley et al. 2008). 
When discussing EPM in the context of this document, the focus will be on S. neurona as 
the etiologic agent of disease. 
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Chapter 3: Immune System and Central Nervous System 
Although it is now possible to confidently diagnose a horse suffering from EPM, this 
gives no indication as to why less than 1% of horses go on to develop clinical disease 
from infection and others can become infected yet remain clinically healthy. 
Because it is not known why some horses are able to control S. neurona infections and 
other go on to develop clinical disease, and the immune system is implicated in this 
differential, it is valuable to examine in further detail the equine immune system and its 
various components. 
This section will focus on the mammalian immune system in general, and form the basis 
of our understanding for subsequent chapters concerning the immune system in response 
to disease. It is not intended to be a comprehensive list of all components at play in the 
immune system as a whole, but merely to address components that could be of 
importance in the response to Sarcocystis neurona infection, based on our knowledge of 
immune responses to related parasites, and of the equine immune system. 
3.1 Overview 
The immune system is a collection of cells and their physiological interactions that 
defend the body from invasion or infection by foreign bodies (Immunisation Advisory 
Centre, 2012; Parham, 2015). The mammalian immune system is comprised of three 
parts main parts: physical barriers, innate immunity, and adaptive immunity. 
Foreign invaders contain antigens on the cell surface, which are recognized by the innate 
immune system, serving as the first line of defense. The innate immune system mounts an 
immediate response that is short lived, non-specific, but capable of eliminating the 
majority of infections (Parham, 2015). More severe infections may overcome the innate 
immunity defense systems. In this case, phagocytic cells, such as the dendritic cells and 
macrophages, present pathogenic antigens on major histocompatibility complexes on 
their cell surface. These receptors are recognized by the adaptive immune system, which 
is able to mount a targeted, antigen specific immune response (Parham, 2015). The 
adaptive immune response is mainly comprised of B cells, which produce antibodies, and 
T cells, which can perform a number of effector functions depending on the type of 
pathogen. T cells are particularly effective at eliminating intracellular threats, such as 
viruses and intracellular bacteria and parasites. B and T cells are able to form memory 
cells, which “remember” a pathogen from primary exposure in order to mount a faster, 
stronger and more targeted response upon secondary exposure (Immunisation Advisory 
Centre, 2012). An effective immune response is usually comprised of a combination of 
both B and T cells. 
3.2 The Central Nervous System and Cerebrospinal Fluid 
The CNS is no different from other tissues in requiring protection from invading 
organisms. Although many of the cell types mediating immune responses are the same in 
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the CNS as in peripheral tissues, the unique nature of the CNS mandates careful 
modulation of these elicited responses (Furr and Reed, 2015; Streilein, 1993). 
Inflammation is used in physiological systems to maintain tissue homeostasis and as a 
defense against pathogens. It is used to initiate death of damaged cells, removal of dead 
cells, to promote healing of damaged areas, and to produce cytokines and chemokines for 
the direction and coordination of immune responses (Carson et al., 2006). This becomes 
tricky in the central nervous system, which is encased in a solid outer layer, and therefore 
cannot tolerate the swelling caused by cellular recruitment to damaged areas. 
Additionally, removal of key neurons, even if damaged, can lead to the cognitive and/or 
motor deficits (Carson et al., 2006). While inflammation caused by an immune response 
is desirable in peripheral tissues, it can cause irreparable damage to the CNS. The CNS is 
therefore delegated an “immunoprivileged” site. 
Immunoprivileged sites are sites in the body that could suffer detrimental consequences 
as a result of the immunogenic inflammatory response, and include the fetoplacental unit, 
the central nervous system, the ovary and testes, and the eye (Streilein, 1993). While 
initially thought to have resulted from passive processes, immune privilege has more 
recently been shown to be the result of active processes derived from immunoregulatory 
and immunosuppressive mechanisms that govern the type of immunity elicited and 
expressed at the site of invasion (Carson et al., 2006; Streilein, 1993). This immune 
regulation is believed to be a physiological adaptation that provides control of infection 
in a privileged site, without the potential deleterious consequences of immunogenic 
inflammation (Streilein, 1993). 
The CNS is coated and protected by cerebrospinal fluid, and is separated both 
functionally and anatomically from the rest of the body by the blood-brain barrier. The 
blood-brain barrier is composed of brain microvascular endothelial cells, astrocytes, and 
pericytes. Tight junctions between endothelial cells are a distinctive feature of this 
barrier, which prevent many molecules from passing through. By controlling the passage 
of molecules, the barrier is able to control the microenvironment in the central nervous 
system, and protect it from pathogens and toxins found in the blood (Carson et al., 2006; 
Kim, 2008). 
The microenvironment is also controlled by the immune privileged site itself, which is 
able to produce soluble factors, thought to be cytokines. When antigens are found in the 
central nervous system, for example, they leave this immune privileged site in 
conjunction with the cytokines, and the cytokines present determine the nature of the 
immune response. The anti-inflammatory cytokine, transforming growth factor beta 
(TGF-β) seems to be particularly important in this regard (Murphy, 2011). 
In the healthy mammal, lymphocytes circulate through the central nervous system as part 
of normal surveillance and protection. These lymphocytes are derived entirely from 
serum, and occur in the CSF in direct proportion those in found in serum, although in far 
lower quantities (Furr, 2002). In diseases of the central nervous system, antibodies are 
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delineations between responses, and that more than two responses are at play in tackling 
pathogenic threats. It has also become clear that there is a complex pattern of cross-
regulation throughout the development of CD4 T cell subsets, described below (Murphy, 
2011). 
Detailed below are key components of the immune response, with particular emphasis on 
those pertaining to the control and/or elimination of intracellular pathogens. It must be 
kept in mind that the plasticity of leukocytes is well documented (Muranski and Restifo, 
2013), and cells may have more than one function, functional overlap, or may switch 
between functions. Similarly, the cytokines that are produced may vary depending on the 
stimulus signal to the expressing cells, and cytokines themselves may be pleiotropic. This 
list is not comprehensive. 
T cells 
Thymus-derived cells, or T cells, are lymphocytes in the adaptive immune response with 
different effector functions. T cells express the T cell receptor (TCR) on their cell 
surface, which is unable to bind antigen directly, and instead relies on presentation by 
antigen presenting cells (APC’s), such as dendritic cells and macrophages. Effector 
differentiation depends on the location in the body (different locations will have different 
APC’s), the nature of the pathogen, and the cytokine environment. 
Major Histocompatibility Complex (MHC) 
MHC molecules are expressed on the surface of cells, and responsible for the 
presentation of antigen for recognition by T cells. These molecules are highly 
polymorphic and vary between individual animals. There are two classes of MHC: Class 
I and Class II. MHC Class I molecules bind to short peptides, 8-10 amino acids in length, 
which come from intracellular pathogens. Class II molecules bind longer peptides, which 
are derived from extracellular pathogens that have been taken up by a phagocytic cell. 
The polymorphism of MHC molecules allows the immune system to respond to a huge 
diversity of pathogens (Murphy, 2011). 
CD8 T cells 
CD8 T cells, or cytotoxic T cells, express glycoprotein CD8 on the cell surface. These 
cells bind to MHC Class I molecules and induce cell death. Because of their destructive 
nature, CD8 T cell activation can result in tissue damage. Therefore, a strong signal is 
required for CD8 T cell activation to ensure that this response is not triggered 
unnecessarily. These cells are activated by dendritic cells or CD4 T cells. Like all T cells, 
proliferation is regulated by IL-2. 
CD8 T cells are crucial in controlling intracellular pathogenic infections – not only do 
they destroy infected cells, but they secrete IFN-γ, which increases intracellular pathogen 
processing and MHC Class I expression (leading to a positive feedback look for 
increased CD8 T cell activation), and activates macrophages, which are important for the 
clearance of dead cells and debris.  
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CD4 T cells 
CD4 T helper (TH) cells are so-called due to the expression of the glycoprotein CD4 on 
the cell surface. These cells are a key component of the adaptive immune response, 
ensuring normal functioning of all parts of the immune system by modulating CD8 T cell 
and B cell responses, and through interaction with the innate arm of the immune system. 
Although some plasticity can occur between them, TH cells are largely polarized to have 
specific effector functions, which are determined by the site of antigenic interaction, 
pathogen type, and the presence or absence of environmental signaling molecules 
(Muranski and Restifo, 2013). TH effector cells are characterized by the expression of a 
master regulator, and the cytokines they produce (Murphy, 2011), and bind to antigen 
presented on MHC Class II molecules. 
Early investigations into the field of immunology classified immune responses as 
predominantly either Type 1 or Type 2 (TH1 or TH2). However, upon the discovery of 
CD4 T cells expressing FoxP3, the addition of regulatory T cells was added to the list of 
polarized T cell responses. More recently, TH17 cells have also been characterized 
(Muranski and Restifo, 2013). Other described T cells include T follicular helper, TH9, 
and TH22 cells, but these go beyond the scope of this paper, and will not be discussed. 
Type I (TH1) Immune Response 
TH1 cells are linked to the cell-mediated arm of adaptive immunity, and their response is 
induced by intracellular pathogens, such as viruses or intracellular bacteria and protozoa 
(Murphy, 2011). The main role of TH1 cells is the activation of macrophages and CD8 
T cells. However, they can also help stimulate B cells in the production of the opsonizing 
or neutralizing antibody subisotypes (Lopez et al., 2003; Murphy, 2011).  
The defining transcription factor for TH1 cells is T-box 21, or T-bet. Their differentiation 
is stimulated by IL-12 and IFN-γ, and they are characterized by the cytokines they 
produce, which are the proinflammatory cytokines IL-12 and IFN-γ, and T cell regulating 
cytokine IL-2. 
TH1 cells operate in part on a positive feedback cycle. They continue to respond to 
signals during an infection, and produce IL-12, a cytokine required for an effective TH1 
immune response (Muranski and Restifo, 2013; Murphy, 2011). Because of their 
proinflammatory nature, TH1 cells are viewed as the main perpetrators of autoimmunity 
(Muranski and Restifo, 2013). 
Type 2 (TH2) Immune Response 
TH2 effector cells are linked to humoral immune responses, and are involved in the 
stimulation of B cells to produce antibodies (Muranski and Restifo, 2013; Murphy, 
2011). The humoral arm of adaptive immunity is responsible for responding to 
extracellular pathogens and parasites, and is also implicated in the development of atopy 
and allergic reactions (Muranski and Restifo, 2013). 
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The defining transcription factor for TH2 cells is GATA3, and they are stimulated to 
differentiate by the cytokine IL-4. TH2 cells are characterized by the cytokines they 
produce, IL-4, IL-5, and IL-13, and to a lesser extent, IL-10 (Muranski and Restifo, 
2013).  
TH2 cells are produced in balance with TH1 cells. The inducing cytokines of TH1 cells 
(IL-12 and IFN-γ), and the TH1 transcription factor (T-bet) inhibit TH2 differentiation. 
Conversely, IL-4 and transcription factor GATA3 stimulate TH2 differentiation but 
inhibit TH1 polarization (Muranski and Restifo, 2013). 
TH17 Effector Cells 
The master regulator of TH17 cells is retinoic acid–related orphan receptor γ thymus 
(RorγT), and they are stimulated to differentiate by transforming growth factor beta 
(TGF-β) and interleukin-6 (IL-6), and the absence of IL-4 and IL-5 (Muranski and 
Restifo, 2013). IL-6 is the key to TH17 differentiation, as without it, regulatory T cells 
will be induced instead of TH17 cells. TH17 cells display site-dependent plasticity, and 
can work in conjunction with TH1 cells to mount a functionally similar immune response. 
They are thought to augment TH1 responses to some intracellular pathogens, such as 
Mycobacteria and Francisella tularensis (Muranski and Restifo, 2013). As with TH1 
cells, TH17 cells have been implicated in the development of autoimmune disease 
(Muranski and Restifo, 2013). However, TH17 cells have higher self-renewal capacity, 
less senescence, and less phenotypic stability (i.e. more plasticity) than TH1 cells 
(Muranski and Restifo, 2013). TH17 cells are characterized by production of the cytokine 
interleukin-17 (IL-17). IL-17 stimulates local tissues to produce an additional 
proinflammatory cytokine, interleukin-8 (IL-8). IL-17 and IL-8 can both often be found 
in a TH17 mediated immune response. Cytokine IL-23 is not required for TH17 
polarization, but stabilizes and expands pathogenic TH17 cells once a TH17 response has 
been established (Murphy, 2011). Cytokines IFN-γ, IL-27, and IL-12 block 
differentiation of TH17 cells (Muranski and Restifo, 2013).  
In the absence of IL-6, naïve T cells will differentiate into regulatory T cells (Butler et 
al., 2013; Murphy, 2011).  
Regulatory T cells (Tregs) 
When a naïve T cell encounters its peptide:MHC ligand in the presence of TGF-β alone 
(i.e. in the absence of IL-6), it differentiates into a regulatory T cell (Murphy, 2011). 
Regulatory T cells are a type of effector CD4 T cell involved in downregulating immune 
reactions. They inhibit responses by other types of T cells, and assist in preventing 
autoimmunity. Treg cells are particularly important in maintaining immune tolerance and 
limiting potentially pathogenic immune reactions (Butler et al., 2013; Murphy, 2011). 
There are various subsets of Tregs, but the two most well-categorized are the natural 
regulatory T cells (nTregs), which are produced in the thymus, and activation-induced 
regulatory T cells (iTregs), which differentiate from naïve CD4 T cells in specific 
cytokine environments in the periphery (Butler et al., 2013; Murphy, 2011). 
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The master regulator of regulator T cells is forkhead box P3 (Foxp3), and their 
differentiation is stimulated by transforming growth factor beta (TGF-β). Tregs are 
characterized by the cytokines they produce, which are the anti-inflammatory IL-10 and 
TGF-β. 
Tregs have a known role in modulating inflammation and limiting immunopathology, and 
are thought to act in maintaining a balance between immune protection and pathology. 
This could be critical in managing diseases affecting the central nervous system, such as 
toxoplasmosis, malaria (Butler et al., 2013), and, potentially, EPM. 
Failure of natural Tregs has been implicated in autoimmunity (Murphy, 2011). 
Table 3.3.1 Summary of four main effector T cell types, inducing cytokines, transcription 
factors, characteristic cytokines produced, and T cell function (Murphy, 2011). 
Effector T Cell TH1 TH17 TH2 Tregs 
Inducing 
cytokines 
IL-12, IFN-γ IL-6, TGF-β IL-4 TGF-β 
Transcription 
Factor 
Tbet RORγT GATA3 FoxP3 
Characteristic 
cytokines 
IL-12, IFN-γ, 
IL-2 
IL-17, IL-6 IL-4, IL-5 TGF-β, 
IL-10 
Function Activate 
macrophages 
Enhance 
neutrophil 
response 
Activates 
cellular and 
antibody 
response to 
parasites 
T cell 
suppressor 
 
B Cells 
B cells are lymphocytes in the adaptive immune response, and are responsible for 
antibody production. B cells express the B cell receptor (BCR) on their cell surface, 
which binds its cognate antigen directly. B cells can also serve as APC’s to T cells. They 
are activated by components of the innate immune system. 
Antibodies 
Antibodies are proteins produced by effector B cells (plasma cells) which bind to 
extracellular pathogens, marking them for neutralization, destruction, or opsonization. 
These Y-shaped proteins have two arms that are capable of binding antigen (Fab region) 
in a highly specific manner, and a region that binds to receptors on other cells (Fc 
region). Antibodies vary by isotype and subisotype, which governs their effector 
function. Mammals have five isotypes: IgA, IgD, IgE, IgG, and IgM. Antibody 
subisotypes vary between species. 
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B Regulatory Cells 
B cells produce antigen-specific antibodies in response to infection. They can also 
negatively regulate immune responses with a subset of B cells called regulatory, or B10, 
cells. B10 cells are named after to their ability to express the regulatory cytokine IL-10 
(Butler et al., 2013; Kalampokis et al., 2013; Yoshizaki et al., 2012). Through IL-10 
production, B10 cells are able to function as critical regulators of TH1-driven 
inflammation, T cell dependent autoimmune disease, and innate and antigen-specific 
adaptive immune responses (Butler et al., 2013; Yoshizaki et al., 2012). They are also 
shown to expand in number and modulate immunity to protozoan infections, such as 
human babesiosis (Kalampokis et al., 2013) and the known immunomodulatory parasite 
schistosomiasis (Tang et al., 2013). Although no research has been conducted into the 
expansion of B10 cells during Plasmodium or Toxoplasma infections, given the critical 
immunoregulation reported on TH1 cells by IL-10 for these two Apicomplexan infections, 
a functional B10 cell role would be unsurprising (Butler et al., 2013). Additionally, given 
the similarity between S. neurona and T. gondii, it would not be improbable to also 
expect a functional role of B10 in S. neurona infections.  
Interferon-γ (IFN-γ) 
IFN-γ is a cytokine of the interferon structural family produced by effector CD4 TH1 
cells, CD8 T cells, and Natural Killer cells. It is the key cytokine for the activation of 
mononuclear cells (macrophages), increases expression of MHC molecules, and 
suppresses TH2 responses (Murphy, 2011; Olias et al., 2013). IFN-γ has been found to be 
significant in host resistance to protozoan diseases, such as toxoplasmic encephalitis and 
cryptosporidiosis (Sellon et al., 2004). Overexpression of IFN-γ can lead to autoimmunity 
(Murphy, 2011). 
When microbes are able to resist the effects of activated macrophages (activated by 
IFN-γ), or if there is insufficient IFN-γ, and therefore insufficient macrophage activation, 
chronic infection can with inflammation can develop in the form of granulomas, which 
are damaging to tissues (Murphy, 2011) 
Interleukin-12 (IL-12) 
IL-12 is most commonly produced by cells of the innate arm of the immune system, and 
is widely recognized as a critical component in influencing adaptive cell-mediated 
immunity by promoting the differentiation and maintenance of CD4 T cells into mature 
TH1 effector cells (Denkers, 2003; Kastelein et al., 2007). IL-12 also activates natural 
killer and CD8 T cells to produce IFN-γ, which further stimulates the differentiation of 
TH1 cells. Numerous studies have illustrated the importance of IL-12 in developing 
protection against intracellular pathogens, such as T. gondii (Denkers, 2003; Kastelein et 
al., 2007). As a component of a TH1 polarized response, IL-12 has also been implicated in 
the development of inflammatory autoimmunity (Kastelein et al., 2007). 
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Transforming Growth Factor- β (TGF-β) 
The primary role of TGF-β in the immune system is to suppress effector T cells and 
promote the differentiation and maintenance of Tregs. By supporting the subsistence of 
Tregs, TGF-β assists in mediating inflammation and maintaining immune tolerance 
through regulation of TH1 cells and cytotoxic CD 8 cells. Because of this 
immunomodulatory role, it has been linked to regulating immunopathogenesis in both 
Plasmodium and Toxoplasma infections, and it would not be unreasonable to assume its 
role in S. neurona infections. The presence of TGF-β is correlated with increased IL-10 
production, and the improved outcome of both severe malarial anemia and cerebral 
anemia, through the suppression of effector T cell activation (Butler et al., 2013; 
Fitzgerald et al., 2007). 
As previously mentioned, when in the presence of IL-6, TGF-β can also trigger 
differentiation of the inflammatory TH17 response, which has the opposite effect of 
suppressing effector T cells, which would happen in the absence of IL-6. TGF-β 
functions in a complex manner to both promote and suppress T cell activity and 
inflammation (Butler et al., 2013). 
TGF-β is produced by CD4 TH2 cells and regulatory cells in conjunction with IL-10, and 
inhibits macrophage activation (Murphy, 2011). In the horse, TGF-β blocks secretion of 
IFN-γ, and suppresses MHC class II expression (Furr and Reed, 2015). The TH2 response 
is therefore critical in modulating the potential overexpression of a TH1 response, the 
occurrence of which could result in tissue damage. 
The importance of TGF-β has been demonstrated in controlling pathology due to 
overactive proinflammatory responses, such as in the case of cerebral malaria (CM). 
Development of CM is associated with TH1 cells, cytotoxic CD8 cells, and cytokine 
storms involving various proinflammatory cytokines. TGF-β suppresses the effector cells 
triggering this immune response, and thereby reduces to severity of CM (Butler et al., 
2013). 
Conversely, lack of TGF-β can also cause pathology. In mice studies conducted on 
Toxoplasma infection of the CNS, it was found that neuronal cells directly respond to 
IL-6 driven inflammation by expressing regulatory cytokines TGF-β and IL-27 (Butler et 
al., 2013). When neuronal cells were blocked from detecting IL-6, they were no longer 
able to express either TGF-β of IL-27, and the mice died as a result of encephalitis 
associated with an uncontrolled TH1 and TH17 cell proliferation in the CNS (Butler et al., 
2013). Under expression of TGF-β has also been linked to autoimmunity (Murphy, 
2011). 
Interleukin-10 (IL-10) 
IL-10 is secreted by regulatory T cells, and acts on effector T cells to inhibit proliferation. 
It also acts on dendritic cells to inhibit secretion of IL-12, which in turn inhibits T cell 
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activation. IL-10 exhibits important immune regulatory functions and suppresses T cell-
mediated inflammation (Fitzgerald et al., 2007; Murphy, 2011). 
Interleukin-6 (IL-6) 
Interleukin-6 is a proinflammatory cytokine that, in conjunction with TGF-β, stimulates 
the differentiation of naïve T cells into TH17 cells. IL-6 is generated by cells of the innate 
immune system, and is regulated by the presence or absence of pathogens. In the absence 
of pathogens, production of IL-6 is low, which favors the differentiation of 
immunosuppressive regulatory T cells, thereby preventing unwanted or overactive 
immune responses (Murphy, 2011). 
Interleukin-17 (IL-17) 
IL-17 is a proinflammatory cytokine, most commonly secreted by TH17 cells, but can 
also be secreted by other cells, including neutrophils. Its effects are mediated though the 
IL-17 receptor, which is expressed on a wide number of cells in the immune system (both 
lymphocytes and neutrophils), as well as other tissue types. IL-17 is a pleiotropic 
cytokine, linking inflammatory effects of the adaptive and innate immune system 
(Muranski and Restifo, 2013). 
Interleukin-27 (IL-27) 
The main sources of IL-27 are thought to be the antigen presenting dendritic cells and 
macrophages, acting during the initial stage of T cell activation (Kimura 2016). Although 
initially considered a proinflammatory cytokine indicative of a TH1 response, IL-27 has 
subsequently been shown to have a predominantly regulatory role in limiting 
immunopathology. This is particularly notable in the parasitic diseases caused by T. 
gondii, T. cruzi, and Plasmodium infections, where IL-27 has a profoundly suppressive 
effect on IL-2 production, thereby inhibiting CD4 cell proliferation. IL-27 suppresses the 
development of the inflammatory TH17 cells, and stimulates the production of regulatory 
cytokine IL-10 (Fitzgerald et al., 2007; Kimura et al., 2016). In mice lacking a functional 
IL-27 receptor, excessive inflammation occurs during infection and autoimmunity.  
3.4 Polarization of Immune Responses 
It is clear that there are many factors that play into an immune response to infection. The 
age old adage of “too much of a good thing is a bad thing” is certainly clear in 
immunology, and it is the balance between all such components that is critical to 
remember. 
The correct functioning of the immune response is a product of millions of years of 
evolution in the face of infections by a diverse array of pathogens (Dent, 2002). The 
polarization of the immune response that is mounted is largely determined by the 
cytokine environment at the time of introduction of a pathogen. Cytokines creating this 
environment may originate from infected or activated somatic cells, or from cells of the 
immune system that have been recruited to the site of infection. Antigen presenting cells, 
30 
 
such as the so-called “professional” antigen presenting dendritic cells, present antigen to 
T cells and deliver the necessary cytokines and co-stimulatory molecules necessary for T 
cell activation (Dent, 2002). Dendritic cells are highly diverse, and can be of either 
myeloid or lymphoid origin, with each sub-type producing differing cytokine profiles, 
and thereby directing immune response polarization (Dent, 2002). 
In addition to the cytokine environment, the immune response may be stimulated in either 
direction by the invading pathogen itself – for example, the lipopolysaccharide-
containing cell wall of gram-negative bacteria directs a TH1 immune response. The 
pathogen may impose an immune bias to promote its own survival and replication in the 
host (Dent, 2002). Therefore, co-infections by other pathogens can also affect the 
cytokine environment. 
3.5 Imbalance of Immune Responses 
There is no single component of the immune system that can in itself resolve pathogenic 
invasion. Rather it is the balance of the various components that lead to either successful 
eradication or tolerance. This section will focus on what happens when the balance gets 
disrupted, drawing from known examples in the literature. 
The primary goal of the immune response is to efficiently and swiftly eradicate the 
pathogen without damaging the host. For intracellular microbial infections, such as T. 
gondii and S. neurona, the default response in immunocompetent hosts is type I 
immunity (TH1 polarized response). In a healthy host, the TH1 response will swiftly clear 
the pathogen, and naturally switch from the production of type I to type II cytokines over 
time, in order to prevent an overly polarized immune response and re-establish 
homeostasis (Spellberg and Edwards, 2001). 
If the type I response is unable to fully clear the intracellular infection, continued 
antigenic stimulation may occur, leading to chronic type I responses and 
immunopathological consequences (most often tissue destruction) (Oldenhove et al., 
2009; Romagnani, 1996; Spellberg and Edwards, 2001). To prevent this from occurring, 
the immune system has regulatory components, such as regulatory T cells. However, in 
some cases, such as pathogen-driven diseases and autoimmune disorders, TH1 cells are 
able to avoid immune regulation (Oldenhove et al., 2009). 
Under-regulation of Th1 and Th17 responses 
TH1 cells and TH17 cells both produce an inflammatory response to pathogens (Kastelein 
et al., 2007). As mentioned, IL-12 stimulates the differentiation of TH1 cells, which in 
turn produce the pro-inflammatory cytokine, IFN-γ. This pathway is predominantly 
cytotoxic, and is important for the direct killing of microbes or infected cells (Kastelein et 
al., 2007). IL-23 stimulates the differentiation of TH17 cells, which in turn produce the 
pro-inflammatory cytokine IL-17. IL-17 stimulates local tissues to produce IL-8, another 
proinflammatory cytokine, and induces the key signs of infection – swelling, heat, and 
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pain, thus setting up an environment conducive to heightened immune responses 
(Kastelein et al., 2007).  
The innate immune system can provoke an immunopathological response without the aid 
of the adaptive immune response. IL-12 and IL-23 are key modulators of this innate 
immunity, with IL-23 directing local inflammation, and IL-12 directing systemic 
responses. In immune privileged organs, such as the central nervous system, 
inflammation requires infiltration of TH17 cells. The initial inflammatory response is 
likely mediated by TH17 cells, and once this initial danger signal has been processed, the 
effector arm of the adaptive immune system is stimulated to promote and influx of 
activated TH1 and CD8 T cells (Kastelein et al., 2007).  
Dysregulated production of pro-inflammatory cytokine IL-17 can result in pathological 
chronic immune-mediated tissue destruction (Kastelein et al., 2007). Because the 
consequence of this IL-23/IL-17 pathway can be immunopathology and/or autoimmune 
inflammation, the evolutionary pressures to conserve such a pathway must be strong. In 
the healthy body, IL-17 is expressed at low levels and likely contributes to the overall 
health of the host and resistance to damage from invading pathogens. After an initial 
heightened inflammatory response by TH17 cells in response to danger, when CD4 and 
CD8 T cells are recruited to the area, a TH1 or a TH2 response will likely become the 
more prominent pathway. This dominance is thought to play a role in ensuring control of 
the inflammatory response so that it does not lead to the breakdown of tissue-specific 
immune tolerance responsible for autoimmune pathology (Kastelein et al., 2007). 
Leprosy 
The development of clinical disease from Mycobacterium leprae infection is a result of a 
TH1/TH2 imbalance (Murphy, 2011). Patients who mount a TH1 immune response to 
infection will control infection and develop the much milder, self-limiting form of 
disease, tuberculoid leprosy. However, if a patient mounts a TH2 response to infection, 
the body will not be able to clear infection, and the result will be the much more severe 
lepromatous leprosy. This is a systemic infection resulting in gross lesions all over the 
body. In patients with lepromatous leprosy, CD8 T cells also play a role in suppressing 
TH1 responses, and producing the cytokines with suppressive capabilities, IL-10 and 
TGF-β (Murphy, 2011) 
Leishmania 
The protozoan parasites Leishmania are also known regulators if the IFN-γ response. 
They inhibit the upregulation of IFN-γ, and the production of IL-12 by macrophages, 
which would be pivotal in mounting a successful Th1 immune response (Sibley, 2011). 
In mice experimentally infected with the protozoan parasite Leishmania, mice that 
mounted a TH1 response to the parasite were immune to disease, whereas mice that 
mounted a TH2 response could not be protected from infection (Spellberg and Edwards, 
2001). 
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Malaria 
As described earlier, IL-27 has a profoundly suppressive effect on the production IL-2, 
which inhibits a T cell response. IL-27 also suppresses development of inflammatory 
Th17 cells, and stimulates the production of regulatory IL-10, making it a critical 
suppressor of immune responses. As with all pathogenic infections, there must be a 
balance between pathogen eradication and host damage. Malaria, one of the most 
important infectious diseases in the world, is caused by the species of protozoan parasite, 
Plasmodium. Malaria has been the focus of much research, not least when it comes to the 
immune system. Protection against malaria infection is largely regulated by CD4 T cells. 
When in the blood-stage form of infection, Plasmodium parasites can exacerbate the 
immune response, resulting in severe pathology. Malaria infection can have an 
immunosuppressive effect, which, while blocking the severe immunopathology just 
mentioned, can also block the protective immune response to the parasite itself, and 
immune responses by other pathogenic agents and vaccines (Kimura et al., 2016). In 
mouse models of malaria infection, a subpopulation of Plasmodium-specific CD4 T cells 
was discovered that produced IL-27 in response to receptor stimulation. By producing IL-
27, IL-2 production was inhibited, and T cell responses were diminished. This indicates 
IL-27 as an immune modulator of responses to Plasmodium infection (Kimura et al., 
2016).  
It would not be unreasonable to propose similar T cell suppression in the immune 
response to S. neurona. 
Toxoplasma gondii 
Toxoplasma gondii is a widespread human pathogen, and has been widely studied. 
Resistance to T. gondii involves both innate immunity and the development of T cell 
responses required to control parasite survival, replication, and persistence (Butler et al., 
2013). The immune response to T. gondii, as with most intracellular pathogens, revolves 
around the production of IL-12, which is the main physiological inducer of IFN-γ and the 
differentiation of TH1 cells (Sacks and Sher, 2002).  A TH1 response is necessary to keep 
parasite populations in check, and T. gondii parasites have evolved mechanisms for 
controlling IL-12 production. The parasites are not only able to suppress IL-12 
expression directly, but can induce expression of the down-regulatory cytokines IL-10 
and TGF-β, and by modulating pro-and anti-inflammatory cytokines can ensure survival 
(Denkers, 2003; Sacks and Sher, 2002). However, unregulated IL-12, and thereby IFN-γ, 
responses from the host can also cause immunopathogenesis to the host, and must be 
controlled. Induction of cytokines IL-10 and IFN-γ as part of the same immune response 
is common with infection by intracellular parasites (Gazzinelli et al., 1996). IL-10 
production is found to be critical to this regulation. Research conducted in mice has 
shown that IL-10 deficient mice may have lower parasite burdens, due to elevated IL-12 
levels, but die from cytokine-associated tissue damage (Butler et al., 2013; Denkers, 
2003; Gazzinelli et al., 1996; Sacks and Sher, 2002). When T cells are appropriately 
activated, they will express inhibitory receptors on their cell surface, which keeps the 
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immune response in balance and is critical for controlling immunopathogenesis (Butler et 
al., 2013). Sustained high levels of IFN-γ, and other proinflammatory cytokines are 
responsible for fever and can initiate cell death and/or damage healthy tissue (Butler et 
al., 2013).  
Research conducted in Sarcocystis Calchasi 
S. calchasi heteroxenous parasite not unlike S. neurona, and cycles between Accipiter 
hawks and domestic pigeons (Columba livia f. domestica). As with S. neurona, S. 
calchasi reproduces sexually in the definitive host (accipiter hawk), and is shed in 
sporocyst form, where it is taken up by the domestic pigeon. When infecting domestic 
pigeons, S. calchasi causes the emerging central-nervous disease pigeon protozoal 
encephalitis (PPE). PPE causes (often fatal) brain lesions and skeletal muscle sarcocysts 
(Olias et al., 2013). 
PPE is biphasic disease in the domestic pigeon, with the first phase resulting in diarrhea 
and apathy, and the second phase causing severe neurological signs and cerebral lesions, 
akin to S. neurona. In research conducted on the immune response to S. calchasi, it was 
found that infectious dose of S. calchasi sporocysts was not correlated to the strength and 
composition of the host immune response. Additionally, it was found that in the first 
phase of the disease, the important TH1 cytokines IL-12, IL-18, IFN-γ, and IL-15 were 
significantly down-modulated. This absence of strong cellular immune response in the 
first stage, and ability to modulate the IL-12/IL-18/IFN-γ pathway, may be a sign of 
parasite evasion, as is seen with other protozoan parasites, such as T. gondii (Olias et al., 
2013; Sacks and Sher, 2002). Also, as with T. gondii, this temporary immune suppression 
seen in the first phase of the disease, may allow the parasite to invade cells undetected, 
and replicate (Olias et al., 2013). 
However, in the neurological second phase of PPE, IFN-γ was significantly up-
modulated. As previously mentioned, IFN-γ is a key cytokine in the activation of 
mononuclear cells, such as lymphocytes and monocytes (Olias et al., 2013). This 
corresponds well with the prominence of T cells detected in the pigeon’s immune system, 
MHC-II signaling in the pigeon’s brain, and the granulomatous nature of the lesions. The 
cerebral lesions are a result of the host’s immune response, triggered by cytokines and 
parasite antigen. Indeed, despite the low parasite load in infected pigeons, there appears 
to be a strong TH1-biased T cell driven immune response, suggesting that a T cell 
mediated delayed-type hypersensitivity reaction may be what causes the cerebral lesions 
and subsequent neurological signs (Olias et al., 2013). 
It is reasonable to assume S. neurona is capable of acting in a similar manner to S. 
calcashi, and that it is in fact the host’s overly polarized TH1 immune response to parasite 
infection that causes lesions of the central nervous system. 
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3.6 Type IV Hypersensitivity (Delayed Hypersensitivity) and Autoimmunity 
Type IV hypersensitivity reactions, or delayed type hypersensitivity reactions, are 
mediated by antigen-specific effector T cells. When TH1 cells recognize their cognate 
antigen on MHC-II antigen presenting cells, they release cytokines, including IFN-γ, 
which further activates T cells, and TNF-α, causing local tissue destruction (Murphy, 
2011). In a healthy animal, this is a desirable response to eliminate intracellular 
pathogens or damaged cells. However, in the case of delayed hypersensitivity, the 
immune response is undesirable, and causes excessive inflammation through the 
activation of macrophages, which release inflammatory cytokines also capable of causing 
inflammatory lesions (Murphy, 2011). 
Genetic differences in MHC II complexes are known to play a role in autoimmunity 
(Murphy, 2011). Research conducted in the intracellular parasite Sarcocystis cruzi has 
shown a correlation between increased MHC II expression on vascular endothelial cells 
and destructive immune responses, such as delayed hypersensitivity reactions (Dubey et 
al., 2016). It is thought that endothelial cells assist in eliciting an overactive immune 
response by processing and presenting antigens on MHC II complexes, resulting in the 
sensitization of T cells (Dubey et al., 2016).  
Autoimmunity due to IL-23/IL-17 pathway  
IL-17 is implicated in several autoimmune diseases. In psoriasis, production of IL-17 by 
resident CD4 T cells encourages the recruitment of other inflammatory cells, such as 
neutrophils, which results in psoriatic lesions (Kastelein et al., 2007; Muranski and 
Restifo, 2013).  
In the disease, Experimental Autoimmune Encephalomyelitis, the mouse model of human 
Multiple Sclerosis, TH17 cells revealed their capacity to induce disease when stimulated 
by IL-23 rather than IL-17. Other human autoimmune diseases were also susceptible to 
IL23-induction of TH17 cells, including inflammatory bowel disease, rheumatoid 
arthritis, uveitis, and allergies (Muranski and Restifo, 2013). Tissue damage caused by 
TH17 cells can either be the result of direct recognition of an antigen-specific target, 
and/or the recruitment of other inflammatory immune components, such as neutrophils 
and macrophages (Muranski and Restifo, 2013). It would appear that when stimulated by 
IL-17, TH17 cells develop into their characteristic phenotype, yet when stimulated by IL-
23, pathogenic TH17 cells usually evolve, displaying TH1-like inflammatory 
characteristics (Muranski and Restifo, 2013). 
The effects of environmental factors, such as toxins, drugs, and co-infection, cannot be 
overlooked in the development of autoimmune disease, although at present, these are 
poorly understood (Murphy, 2011). 
3.7 Research in SCID animal models 
Animals with severe combined immunodeficiency syndrome (SCID) make useful 
research tools when studying the immune system. While SCID mice are the traditional 
35 
 
research tool, Arabian SCID foals can be used in studying equine diseases. Arabian 
horses with SCID lack T and B cells due to a DNA mutation, and have been used 
experimentally in determining the role of the adaptive immune response in disease 
development of equine infectious anemia and equine piroplasmosis (Sellon et al., 2004). 
Studies conducted in SCID mice infected with Sarcocystis neurona found SCID mice to 
be resistant to encephalitis, while immunocompetent mice were susceptible (Marsh et al., 
1997). 
SCID foals were successfully infected with the S. neurona parasite, and subsequently, 
parasites were found in the host blood and tissue. However, whether the mode of 
infection was oral or intravenous, S. neurona was undetectable in tissues of the central 
nervous tissue of these foals, and none of them developed clinical signs of EPM (Dubey 
et al., 2015; Sellon et al., 2004). This is in contrast to immunocompetent animals, which 
are able to successfully control parasitemia and clear infection from visceral tissues, but 
in whom parasites are often found in the central nervous system, and clinical signs of 
neurological disease are common (Sellon et al., 2004). 
This research in both SCID mice and horses demonstrates the role of the adaptive 
immune system in the development of S. neurona infection and disease. The adaptive 
immune response is important in controlling parasite replication, as shown by the 
immunocompetent animals’ ability to limit parasitemia and visceral tissue invasion, but 
may not be as important in controlling neuroinvasion, as shown by the presence of 
parasites in the CNS of immunocompetent animals but not SCID animals (Dubey et al., 
2015; Sellon et al., 2004).  
While the adaptive immune response may not be responsible for controlling 
neuroinvasion, should neuroinvasion occur, the adaptive immune response could well be 
implicated in the development of CNS lesions and clinical disease. 
3.8 The equine immune system 
Immunoglobulin isotypes are defined by amino acid differences in the constant region of 
the heavy chain. Different isotypes, and subisotypes, have different biological functions, 
including complement fixation and the binding of phagocytic cells (Sheoran et al., 2000).  
The isotype immunoglobulin G (IgG) is the predominant antibody class in equine serum, 
and is a critical component of immune response to both intracellular equine pathogens, 
such as equine herpesvirus, Rhodococcus equi, and Theileria equi, and extracellular 
pathogens, such as nematodes (Keggan et al., 2013). In the horse, IgG has four 
subisotypes – IgGa, IgGb, IgGc, and IgG(T). 
In adult horse serum, IgGb is the predominant isotype. Consisting of over 60% of total 
isotype concentration, it is significantly higher than all other subisotypes. Subisotypes 
IgGa and IgG(T) occurred at significantly higher concentrations to IgGc, which occurs at 
the less than 1% of total isotype concentration, as demonstrated in Figure 3.9.1 (Sheoran 
et al., 2000). 
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Table 3.8.1 Original and updated classification of equine IgG subisotypes (Wagner, 
2006). 
Original Subisotype 
Classification 
Updated Subisotype 
Classification 
IgGa IgG1 
IgGb IgG4, IgG7 
IgGc IgG2 
IgG(T) IgG3, IgG5 
 
IgGa and IgGb have been demonstrated to be the most important equine antibody 
subisotypes in eliciting a protective response against intracellular pathogens, and are 
therefore indicative of a type I, cell-mediated immune response.  Isotypes IgGc and 
IgG(T) are thought to be indicative of a type II, humoral immune response (Keggan et al., 
2013; Lewis et al., 2008). 
IgGc is detected in very low serum concentrations of the clinically normal horse, and in 
horses infected with Streptococcus equi and equine influenza virus, and is not able to 
bind complement. It is, therefore, considered to be the least important equine IgG 
subclass in protective humoral immune responses (Sheoran et al., 2000). 
As a consequence of equine genome sequencing, equine subisotypes have been 
reclassified according to their position on the chromosome. Research has shown seven 
genes for IgG constant heavy chains, which correspond to the original nomenclature as 
described in Figure 3.2.2. 
Table 3.8.2 Data showing equine serum IgG and subisotype concentrations (Sheoran et 
al., 2000). 
Antibody Quantity 
(mg/ml) 
IgG 27.2 
IgGa 3.4 
IgGb 19.6 
IgGc 0.2 
IgG(T) 4.0 
 
Due to the limitation of materials available for use in equine research, monoclonal 
antibodies were used in this research with the original designations of IgGa, b, and (T), 
and such nomenclature shall be used throughout this document. 
3.9 Antibody subisotypes as proxies for TH1 vs TH2 Immune Responses 
Immunoglobulin subisotype profiles are useful as immunological markers in indicating 
the overall type of immune response (TH1 or TH2) being mounted by the host animal. 
This is evaluated particularly noting by the differences between levels of IgGa, IgGb, and 
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IgG(T). In horses infected with the Apicomplexan Babesia equi (Theileria equi), 
successful eradication of parasitemia occurred with a prevalence of subisotypes IgGa and 
IgGb (Cunha et al., 2006). This was indicative of a TH1 response, dependent on the 
production of interferon gamma (IFN-γ) by T cells (Cunha et al., 2006).  
In horses infected with equine influenza virus, protective immunity generated by natural 
infection is associated with IgGa and IgGb subisotype responses. When an IgG(T) 
response is elicited, as by vaccination, clinical signs and viral shedding occur (Nelson et 
al., 1998). This demonstrates well the important of having the correct subisotype 
response to infection. 
Knowledge of the protective immune response required to eliminate or control 
pathogenic infection provides a basis for rational vaccine design, where the end goal is 
for optimal stimulation of functionally effective antibodies (Sheoran et al., 2000). By 
measuring which antibody subisotype classes are present in their respective 
concentrations, an idea of which immune response is being mounted can be formulated.  
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Chapter 4: Analysis of humoral immune responses in horses with equine protozoal 
myeloencephalitis. 
4.1 Introduction 
Equine protozoal myeloencephalitis (EPM) is one of the most important neurological 
diseases of horses in the Americas (Dubey et al., 2015), and is most commonly caused by 
the protozoan parasite Sarcocystis neurona. In general, Sarcocystis species convey low 
pathogenicity, and infections are well tolerated (Dubey et al., 2016). While the 
seroprevalence of S. neurona in horses is high, EPM occurs in less than 1% of the 
infected horses (NAHMS, 2001). Clinical signs of EPM can vary, and antemortem 
diagnosis has proven challenging. Although EPM is usually a progressively debilitating 
disease with a gradual onset, this varies widely from horse to horse. The disease may 
stabilize in some horses, remaining static for periods of time, but can have a rapid onset 
with focal or multifocal signs of neurologic disease in others (Dubey et al., 2015). Early 
clinical signs of disease can include stumbling, and are often confused with hind end 
lameness (Dubey et al., 2015). The presence of serum antibodies against S. neurona is an 
indicator of infection but not necessarily disease. It is, therefore, apparent that neurologic 
disease is not the outcome of every S. neurona infection. Upon necropsy, parasites can be 
numerous and easily found in the central nervous system (CNS) in some EPM cases. 
However, other cases may present with severe lesions despite parasites that are sparse or 
non-detectable. This implies that pathogenesis is, at least in part, immune-based (Dubey 
et al., 2015; Furr and Reed, 2015). 
The correct functioning of the immune response is a product of millions of years of 
evolution in the face of infections by a diverse array of pathogens (Dent, 2002). There is 
no single component of the immune system that can alone resolve pathogenic invasion – 
rather it is the balance of the various components that lead to either successful eradication 
or tolerance. The primary goal of the immune response is to efficiently and swiftly 
eradicate the pathogen without damaging the host. Polarization of an immune response 
means that cells become specialized to perform specific functions in response to the 
particular type of pathogen encountered. For intracellular microbial infections, such as 
Toxoplasma gondii and S. neurona, the default response in immunocompetent hosts is 
type I immunity (TH1 polarized response). In a healthy host, the TH1 response will swiftly 
clear the pathogen, and naturally switch from the production of type I to type II cytokines 
over time in order to prevent an overly polarized immune response and re-establish 
homeostasis (Spellberg and Edwards, 2001). If the THI response is unable to fully clear 
the intracellular infection, continued antigenic stimulation may occur, leading to chronic 
TH1 responses and immunopathological consequences (most often tissue destruction) 
(Oldenhove et al., 2009; Romagnani, 1996; Spellberg and Edwards, 2001). 
Aberrant immune responses to pathogenic organisms are well documented. The 
development of clinical disease from Mycobacterium leprae infection is a result of a 
TH1/TH2 imbalance (Murphy, 2011). If a TH1 immune response is mounted, infection will 
be controlled and the patient will develop the much milder, self-limiting form of disease, 
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tuberculoid leprosy. However, a TH2 response will not clear infection, resulting in the 
much more severe lepromatous leprosy. Similarly, in mice experimentally infected with 
the protozoan parasite Leishmania, a TH1 response provides immunity to disease, 
whereas a TH2 response does not protect the mice from infection (Spellberg and Edwards, 
2001). In horses infected with equine influenza virus, protective immunity generated by 
natural infection is associated with IgGa and IgGb subisotype responses. When an IgG(T) 
response is elicited, as by vaccination, clinical signs and viral shedding occur (Nelson et 
al., 1998). 
The variety and amplitude of antibodies produced during an infection are largely 
influenced by this TH1 or TH2 bias, and bias in the “wrong” direction could lead to 
disease. As such, an in-depth examination of antibody responses may reveal aberrations 
in the immune status of horses that are actively infected with S. neurona and afflicted 
with neurological disease. The isotype immunoglobulin G (IgG) is the predominant 
antibody class in equine serum, and is a critical component of immune response to both 
intracellular and extracellular equine pathogens (Keggan et al., 2013). In the horse, four 
IgG subisotypes have been described – IgGa, IgGb, IgGc, and IgG(T). IgGa and IgGb 
have been demonstrated to be the equine antibody subisotypes associated with the 
protective response against intracellular pathogens, and are therefore indicative of a type 
I, cell-mediated immune response.  Isotypes IgGc and IgG(T) are thought to be indicative 
of a type II, humoral immune response (Keggan et al., 2013; Lewis et al., 2008). 
As mentioned above, infection of horses by S. neurona is fairly common, but the annual 
incidence of EPM is quite low (less than 1%). We hypothesize that EPM occurs due to an 
aberrant immune response, which will be discernable in the IgG subisotypes that 
recognize S. neurona in EPM positive horses versus infected but clinically healthy 
horses.   
4.2 Materials and Methods 
Serum and CSF 
Serum was collected from 116 clinically healthy horses on the University of Kentucky 
Research Farm. CSF from 30 EPM-negative (infected normal) horses was provided by 
the Equine Diagnostic Solutions (EDS). Ninety-three serum samples and 91 CSF samples 
from horses diagnosed with clinical EPM (infected diseased) were also provided by EDS. 
The cut-off for diseased horses was determined at a CSF:serum antibody ratio of 1:25 
(Reed et al., 2013). To ensure a positive serum antibody titer for infected normal horses, 
the cut-off for a percent positivity was determined to be 10%, as previously demonstrated 
(Yeargan et al., 2015).  
Enzyme-Linked Immunosorbent Assays (ELISAs) 
The S. neurona trivalent recombinant protein rSnSAG2/4/3 was produced and used as 
antigen in the ELISAs. The S. neurona positive control serum was from a clinically 
affected horse that had EPM confirmed by postmortem examination. The negative control 
40 
 
serum was from a pre-infection foal used in a prior infection experiment. All samples 
were tested in duplicate wells. 
Unknown Samples 
Corning high-binding, 96-well plates were coated with antigen and incubated overnight at 
4°C. Antigen was diluted at 1:800 with PBS, as per Bradford Assay results to determine 
the correct concentration for antigen use.  
After overnight incubation, the antigen was removed from the wells and plates were 
rinsed three times with PBS–0.05% Tween 20 (PBST). Wells were blocked by incubating 
for 1 hour at room temperature (RT) with 200 μl PBS containing 1.0% Tween 20, 
5% NGS, and 0.01 g/ml nonfat dry milk. After one wash, 50 µl of primary sera or CSF 
were added to the wells containing antigen. Sera and CSF were diluted with antibody 
diluent (1:10 mix of block solution with PBST) in a two-fold dilution series described in 
Table 4.2.1. 
Table 4.2.1 Serum and CSF dilutions used against rSnSAG2/4/3 antigen to test antibody 
concentrations in infected normal and infected diseased horses. 
Subisotype Serum 
Dilution 
CSF 
Dilution
Subisotype Serum 
Dilution 
CSF 
Dilution 
Total IgG 1:400 1:12.5 IgGb 1:25 1:6.25 
 1:800 1:25  1:50 1:2512.5 
 1:1,600 1:50  1:100 1:25 
      
IgGa 1:100 1:6.25 IgG(T) 1:12.5 1:6.25 
 1:200 1:12.5  1:25 1:12.5 
 1:400 1:25  1:50 1:25 
 
These dilutions were previously determined empirically to most often show an optical 
density (OD) within the typical working range, between 0.5 and 2.5 OD. The plate was 
incubated for 1 h at 37 °C. After five washes with PBST, 75 µl of monoclonal antibodies 
IgGa, IgGb, and IgG(T) (Lunn et al., 1995) diluted with antibody diluent were added to 
the appropriate wells at dilutions described in Table 4.2.3. 
Table 4.2.2 Monoclonal antibody dilutions for IgG subisotypes. 
Subisotype Concentration 
IgGa 1:16 
IgGb 1:128 
IgG(T) 1:16 
 
The dilutions of these monoclonal antibodies were previously determined empirically to 
give data within the best working range of OD. 
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The plate was incubated for 1 h at 37 °C. After five washes with PBST, 75 μl of HRP-
conjugated goat anti-horse IgG diluted to 1:5,000 with antibody diluent was added to the 
standard curve wells, and HRP-conjugated goat anti-mouse IgG diluted to 1:10,000 with 
antibody diluent was added to the unknown sample wells. The plate was again incubated 
for 1 hour at 37 °C. After washing the wells five times, 75 μl of the chromagenic 
substrate TMB (3,3′,5,5′,-tetramethylbenzidine; Pierce, Thermo Fisher Scientific, Inc.) 
was added to each well, and color was allowed to develop for 10 min at RT in the dark. 
The reaction was stopped by the addition of 75 μl of 1 M sulfuric acid, and the OD was 
measured at 450 nm in an Emax microplate reader (Molecular Devices). 
Standard Curves 
Standard curves were generated using a pooled serum sample from 21 healthy horses of 
mixed gender, age, and breed (kindly provided by Dr. Alex Estellar-Vico, University of 
Kentucky, Lexington, KY, USA).  Pooled serum was also diluted in PBS, and the wells 
were coated to create standard curves in a two-fold dilution series, as shown in Table 
4.2.3. 
Table 4.2.3 Serum dilutions used to create standard curves for total IgG and IgG 
subisotypes a, b, and (T). 
Subisotype Pooled Serum 
Dilution 
Subisotype Pooled Serum 
Dilution 
Total IgG 1:640,000 IgGb 1:160,000 
 1:1,280,000  1:320,000 
 1:2,560,000  1:640,000 
 1:5,120,000  1:1,280,000 
 1:10,240,000  1:2,560,000 
    
IgGa 1:160,000 IgG(T) 1:320,000 
 1:320,000  1:640,000 
 1:640,000  1:1,280,000 
 1:1,280,000  1:2,560,000 
 1:2,560,000  1:5,120,000 
 
Wells were coated with 75 µl pooled serum and incubated overnight at 4°C. Standard 
curves were generated based on previously determined serum concentrations, shown in 
Table 4.1.4.  Blocking, washing, and antibody detection was conducted the same as 
above. 
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Table 4.2.4 Mean (± SD) serum concentrations (mg/ml) of immunoglobulin isotypes and 
27 adult mixed-breed horses (Sheoran et al., 2000) 
Immunoglobulin Serum Concentration 
(mg/mL) 
IgGa 3.4 ± 2.0 
IgGb 19.6 ± 6.5 
IgG(T) 4.0 ± 2.5 
 
Calculations 
The standard curve was plotted in excel. A polynomial trend line with an R2 value of 0.95 
or higher was added, and the curve equation exhibited on the graph. The equation was 
then used to plot the data of unknown serum and CSF samples, with the ‘y’ variable as 
antibody amount (ng), and the ‘x’ variable as the OD reading given by the microplate 
reader. From these readings, the antibody concentration was calculated using the 
following equation: 
Antibody concentration (mg/mL) = Antibody amount (ng) * dilution factor / µl serum 
used in well * 0.001 (Equation 1) 
The average of three possible positive values for each sample were used. If one or more 
value was negative, these values were excluded from the average. If all three values were 
negative, the sample was recorded as showing missing data. 
Statistical Analysis 
Data was analyzed as a nested design using PROC GLIMMIX in SAS 9.4 (Carny, 
NC).  Individual horse was used as replicates and were nested within their respective 
treatment groups (i.e. either infected normal or infected diseased).  Mean comparisons 
between treatment groups was done using least significant difference.  Linear regressions 
were conducted between (Y-variables) and (X-variables) using PROC 
REG.  Significance of all analyses were made at a P < 0.05 level. 
4.3 Results 
Since ELISA’s are semi-quantitative, standard curves were set up to more precisely 
measure the amount of S. neurona-specific total IgG and IgG subisotypes a, b, and (T) in 
equine serum samples. As shown in Figures 4.3.1 and 4.3.2, total amounts of antigen-
specific IgG, IgGa, IgGb, and IgG(T) were determined for the infected diseased and 
infected normal groups of horses. No difference in amounts of antigen-specific IgG, 
IgGa, and IgGb were observed between the infected diseased and infected normal group. 
However, a significant difference (p < 0.05) was observed between the two groups for 
IgG(T), with the infected normal group having higher concentrations of IgG(T) than the 
infected diseased group. These results suggest a lower TH2 response in infected diseased 
horses. 
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Next, ratios between the IgG subisotypes were determined for the infected normal and 
infected diseased groups, with the aim of showing a bias in immune response. As shown 
in figure 4.3.2, there were no significant differences in the ratios of IgGa to IgGb, IgGb to 
IgG(T), or combined IgGa and IgGb to IgG(T) between groups. However, there was a 
significant difference in the ratio of IgGa to IgG(T), with infected diseased horses having 
a higher ratio than infected normal horses. This finding is consistent with infected 
diseased horses having a lower concentration of IgG(T) than infected normal horses, and 
suggest a bias towards a TH1 and/or away from a TH2 response in the infected diseased 
horses. 
Because the central nervous system is separated both functionally and anatomically from 
the rest of the body, the IgG subisotypes in both serum and CSF of infected diseased 
horses were analyzed to determine whether responses were compartmentalized and 
showed a difference between the intrathecal immune response and the systemic immune 
response to S. neurona (Figure 4.3.4). The CSF data from one horse were excluded from 
the analysis as an outlier (horse 90).  Significant differences were found in the ratios of 
IgGa to IgGb and IgGa to IgG(T) (p < 0.05) between serum and CSF, with these ratios 
being higher in CSF. Results from this analysis show that there is a significant difference 
between intrathecal and systemic immune responses, and suggest a bias toward a TH1 
response in the central nervous system. 
CSF data was analyzed for the infected normal group of horses but antibody 
concentrations were undetectable and therefore not useful for further analysis. 
Since differences in IgG subisotypes were observed between infected diseased and 
infected normal horses, we examined the possibility of developing a simple serum test for 
identifying EPM diseased horses. For IgG(T) concentrations, a 0.05 ng/ml cut-off yielded 
specificity of 57% and sensitivity of 18% for EPM diagnosis (Figure 4.3.5). Increasing 
the cut-off to 0.15ng/ml provided 80% specificity but only 10% sensitivity These results 
indicate that an IgG(T) serum test will have little diagnostic value for EPM. 
The ratio of IgGa to IgG(T) was higher in infected diseased horses, so its diagnostic 
potential was also evaluated (Figure 4.3.6). With a ratio of 100:1 IgGa to IgG(T) as the 
cut-off for determining EPM, specificity was 67% but sensitivity was only 2%. With a 
ratio cut-off of 25:1 IgGa to IgG(T), specificity was 56% and sensitivity was 16%. Based 
on these results, a ratio of IgGa to IgG(T) serum test will have little diagnostic value for 
EPM. 
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Figure 4.3.1 Difference in total immunoglobulin G (IgG) (µg/ml) in the serum of 
infected normal and infected diseased horses. IgG concentration in infected normal 
horses was 0.005 μg/ml (SE ± 0.001 μg/ml), and IgG concentration in infected 
diseased horses was 0.004 μg/ml (SE ± 0.001 μg/ml), with no significant difference 
between concentrations detected (p = 0.2069). 
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Figure 4.3.2 Difference in 
immunoglobulin G (IgG) 
subisotype concentrations (ng/ml) 
in the serum of infected normal 
and infected diseased horses. A) 
IgGa concentration in healthy 
horses was 0.256 ng/ml (SE ± 
0.026 ng/ml), and IgGa 
concentration in diseased horses 
was 0.238 ng/ml (SE ± 0.029 
ng/ml), with no significance 
between concentrations detected (p 
= 0.6544). B) IgGb concentration 
in healthy horses was 4.562 ng/ml 
(SE ± 0.514 ng/ml), and IgGb 
concentration in diseased horses 
was 3.773 ng/ml (SE ± 0.572 
ng/ml), with no significance 
between concentrations detected (p 
= 0.3065). C) IgG(T) 
concentration in healthy horses 
was 0.048 ng/ml (SE ± 0.005 
ng/ml), and IgG(T) concentration 
in diseased horses was 0.031 ng/ml 
(SE ± 0.006 ng/ml), with a 
significant difference between 
concentrations detected (p = 
0.0359). 
 
* 
* 
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Figure 4.3.3 Difference between immunoglobulin G (IgG) subisotype concentration 
ratios in the serum of infected normal and infected diseased horses. A) The ratio of IgGa 
to IgGb in infected normal horse serum was 0.099 (SE ± 0.012), and the ratio of IgGa to 
IgGb in diseased horse serum was 0.111 (SE ± 0.013), with no significance between 
ratios detected (p = 0.4705). B) The ratio of IgGa to IgG(T) in infected normal horse 
serum was 11.275 (SE ± 2.357), and the ratio of IgGa to IgG(T) in diseased horse serum 
was 18.543 (SE ± 2.667), with a significant difference between ratios detected (p = 
0.0425). C) The ratio of IgGb to IgG(T) in infected normal horse serum was 184.580 
(SE ± 43.783), and the ratio of IgGb to IgG(T) in diseased horse serum was 301.850 (SE 
± 49.741), with the difference between ratios approaching significance (p = 0.0783). D) 
The ratio of IgGa plus IgGb to IgG(T) in infected normal horse serum was 197.350 (SE 
± 46.019), and the ratio of IgGa plus IgGb to IgG(T) in diseased horse serum was 
320.390 (SE ± 52.045), with the difference between ratios approaching significance (p = 
0. 0781). 
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Figure 4.3.4 Difference between immunoglobulin G (IgG) subisotype concentration 
ratios in the serum and cerebrospinal fluid (CSF) of infected diseased horses. A) The 
ratio of IgGa to IgGb in CSF was 0.274 (SE ± 0.033), and the ratio of IgGa to IgGb in 
serum was 0.114 (SE ± 0.032), with a significant difference between ratios detected 
(p = 0.0007). B) The ratio of IgGa to IgG(T) in CSF was 33.033 (SE ± 5.084), and the 
ratio of IgGa to IgG(T) in serum was 18.669 (SE ± 4.272), with a significant 
difference between ratios detected (p = 0.032). C) The ratio of IgGb to IgG(T) in CSF 
was 258.57 (SE ± 78.180), and the ratio of IgGb to IgG(T) in serum was 302.88 (SE 
± 65.685), with no significant difference between ratios (p = 0.665). D) The ratio of 
IgGa plus IgGb to IgG(T) in CSF was 291.600 (SE ± 82.085), and the ratio of IgGa 
plus IgGb to IgG(T) in serum was 321.54 (SE ± 68.965), with no significant 
difference between ratios (p = 0.780). 
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Figure 4.3.5 Serum IgG(T) concentrations in infected diseased and infected normal 
horses to determine the diagnostic potential of IgG(T) for a serum-based diagnostic test.  
 
Figure 4.3.6 Serum IgGa/IgG(T) ratios in infected diseased and infected normal horses to 
determine the diagnostic potential of a serum-based test using IgGa/IgG(T) ratio.  
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4.4 Discussion 
Why most horses infected with S. neurona remain clinically unaffected while a small 
proportion develop EPM has remains a major barrier in the understanding and control of 
the disease. The purpose of this study was to assess the immune response in horses 
seropositive for S. neurona, and compare those that develop clinical disease with those 
that were infected but remained normal. The rSnSAG2/4/3 ELISA was used and 
modified to detect amounts of IgG and subisotypes in serum from these two groups of 
horses. Collectively, our results suggest that infected diseased horses have an immune 
response biased towards a TH1 response relative to horses that have been infected but 
remained clinically unaffected.   However, it is currently unclear whether it is the 
difference in immune responses that is causing the development of clinical disease, or 
whether the chronic CNS infection by S. neurona is leading to a change in the immune 
response. 
It is well established that an imbalance in immune responses can result in clinical disease. 
Development of clinical disease from the intracellular pathogen Mycobacterium leprae 
infection is a result of a TH1/TH2 imbalance (Murphy, 2011). Protozoan parasites 
Leishmania spp. and T. gondii are also known immunomodulators, with a TH2 response 
to Leishmania resulting in uncontrolled infection, and an overly polarized TH1 response 
to T. gondii resulting in immunopathogenesis (Butler et al., 2013; Spellberg and Edwards, 
2001). 
A disease known as Pigeon Protozoal Encephalitis (PPE) caused by Sarcocystis calchasi 
has recently been documented in the domestic pigeon (Columba livia f. domestica). PPE 
is a biphasic disease, with the second phase causing severe neurological signs and 
cerebral lesions, similar to EPM (Olias et al., 2013). The cerebral lesions are a result of 
the host’s immune response, triggered by cytokines and possibly parasite antigen. Despite 
the low parasite load in infected pigeons, there appears to be a strong TH1-biased, T cell 
driven immune response, suggesting that a T cell-mediated delayed-type hypersensitivity, 
or type IV hypersensitivity, reaction may be what causes the cerebral lesions and 
subsequent neurological signs (Olias et al., 2013). Delayed type hypersensitivity 
reactions are mediated by antigen-specific effector T cells. When TH1 cells recognize 
their cognate antigen on MHC-II antigen presenting cells, they release cytokines, 
including IFN-γ, which further activates T cells, and TNF-α, causing local tissue 
destruction (Murphy, 2011). In a healthy host, this is a desirable response to eliminate 
intracellular pathogens or damaged cells. However, in the case of delayed-type 
hypersensitivity, the immune response causes excessive inflammation and inflammatory 
lesions (Murphy, 2011).  It is reasonable to hypothesize that S. neurona infection in EPM 
horses is similar to S. calcashi infection of pigeons, and that it is the host’s overly 
polarized TH1 immune response to parasite infection that causes lesions of the central 
nervous system. 
The findings of this study are consistent with research conducted in severe combined 
immunodeficient (SCID) foals infected with S. neurona. In SCID foals, S. neurona was 
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undetectable in tissues of the central nervous tissue, and none of them developed clinical 
signs of EPM (Dubey et al., 2015; Sellon et al., 2004). Immunocompetent animals 
infected with S. neurona were successfully able control parasitemia and clear infection 
from visceral tissues, but parasites were often found in the central nervous system, and 
clinical signs of neurological disease were common (Sellon et al., 2004). The infection 
study with SCID foals show importance of TH1 response in immunopathology, which is 
consistent with findings for Sarcocystis calchasi infection and PPE (Olias et al., 2013).  
The results from this study are in contrast to prior studies examining cell-mediated 
immune responses in EPM-positive and EPM-negative horses (Spencer et al., 2005; 
Spencer et al., 2004). The 2004 study looked at lymphocyte responses in vitro, and found 
that IFN-γ was reduced in horses with clinical EPM, indicative of a reduced TH1 response 
in diseased horses. The 2005 study also found an increase in IL-4 production, indicative 
of a higher TH2 response, contrary to what we observed. The results from the current 
study are also in contrast to previous work looking at horses experimentally infected with 
S. neurona (Lewis et al., 2014; Witonsky et al., 2008). These studies found decreased 
cell-mediated immune (TH1) responses as the result of experimental infection, although 
the 2014 study did note an inability to distinguish a unique and consistent change in 
equine immune response. The differences between the present study’s results and these 
previous studies could be explained by the difference in research methods: the results of 
the present study were observatory from live, infected animals, whereas the results of 
previous studies were from in vitro stimulation of lymphocytes and examination of 
experimental infection in horses. 
Inappropriate cross-regulation 
Although the immune response has traditionally been characterized as either TH1 or TH2, 
the response is far more complex, involving other important T cell subsets, such as TH17 
and regulatory T cells (Tregs) (Murphy, 2011).  
TH17 cells display site-dependent plasticity, and can work in conjunction with TH1 cells 
to mount a functionally similar immune response. They are thought to augment TH1 
responses to some intracellular pathogens, such as Mycobacteria and Francisella 
tularensis (Muranski and Restifo, 2013). In immune privileged organs, such as the central 
nervous system, inflammation requires infiltration of TH17 cells. The initial inflammatory 
response is likely mediated by TH17 cells, and once this initial danger signal has been 
processed, the effector arm of the adaptive immune system is stimulated to promote and 
influx of activated TH1 and CD8 T cells (Kastelein et al., 2007). TH17 cells are 
characterized by production of the cytokine interleukin 17 (IL-17). IL-17 stimulates local 
tissues to produce an additional proinflammatory cytokine, interleukin-8 (IL-8). IL-17 
and IL-8 can both often be found in a TH17 mediated immune response that induces the 
key signs of infection – swelling, heat, and pain, thus setting up an environment 
conducive to further heightened immune responses (Kastelein et al., 2007). Dysregulated 
production of pro-inflammatory cytokine IL-17 can result in pathological chronic 
immune-mediated tissue destruction (Kastelein et al., 2007), and IL-8 was seen to be 
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upregulated in S. calchasi infection (Olias et al., 2013). It is, therefore, possible, that the 
dysregulation of TH17 cells plays a role in EPM. 
Tregs have a known role in modulating inflammation and limiting immunopathology, and 
are thought to act in maintaining a balance between immune protection and pathology. In 
some cases, such as pathogen-driven diseases and autoimmune disorders, TH1 cells avoid 
immune regulation (Oldenhove et al., 2009). Therefore, Tregs could be critical in 
managing diseases affecting the central nervous system, such as toxoplasmosis, malaria 
(Butler et al., 2013), and, potentially, EPM. 
Coinfection 
Protozoal parasites are not the only pathogens known to modulate immune responses. 
Concurrent infections by both pathogenic and non-pathogenic organisms are ubiquitous 
in nature, and in horses infected with S. neurona, it is possible that this microenvironment 
is a result of coinfection with another organism (Ezenwa and Jolles, 2011). For example, 
helminths are known immunomodulators, and tend to skew the immune response in the 
direction of a TH2 type response  (Dent, 2002; Ezenwa and Jolles, 2011). In contrast, 
viruses tend to skew the immune response in the direction of a TH1 type response, while 
simultaneously subduing regulatory responses (Dent, 2002; Romagnani, 1996). Given 
that a lower TH2 response and TH1 dominant response is seen in horses that are infected 
with S. neurona and go on to develop clinical disease, the presence or absence of other 
infectious organisms could be part of the etiology of EPM.   
Future Directions 
In summary, it has now been demonstrated that the immune response to S. neurona may 
play a role in EPM pathogenesis. However, it is not currently clear what is causing the 
difference in immune responses between infected normal and infected diseased horses. 
Whether disease is a result of the difference in immune response or whether the 
difference in immune response is the result of disease still needs to be further elucidated. 
Additionally, further research is required into the factors driving the difference in 
immune response, and what makes certain horses more susceptible to the development of 
disease. Cytokine profiles in infected normal and infected diseased horses could be 
compared, particularly when examining the potential of TH17 and Tregs cells in causing 
immunopathogenesis. Investigation into coinfections by other organisms may also lead to 
better understanding of why the difference in immune responses occurs. 
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